16 May 2022
EMA/CHMP/234723/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Draft agenda for the meeting on 16-19 May 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

16 May 2022, 13:00 – 19:30, virtual meeting/room 1C

17 May 2022, 08:30 – 19:30, virtual meeting/room 1C

18 May 2022, 08:30 – 19:30, virtual meeting/room 1C

19 May 2022, 08:30 – 15:00, virtual meeting/room 1C

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 16-19 May 2022. See May 2022 CHMP minutes (to be published post June 2022 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 16-19 May 2022.

1.3. Adoption of the minutes

CHMP minutes for 19-22 April 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 10 May 2022.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. melphalan flufenamide - Orphan - EMEA/H/C/005681

Oncopeptides AB; treatment of multiple myeloma

Scope: Possible oral explanation

Action: Possible oral explanation to be held on 17 May 2022 at 14:00

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 16.09.2021.

2.1.2. tezepelumab - EMEA/H/C/005588

add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma

Scope: Possible oral explanation

Action: Possible oral explanation to be held on 17 May 2022 at 16:00

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 14.10.2021.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.4. Referral procedure oral explanations

2.4.1. Daruph and Anafezyn - dasatinib (anhydrous) - EMEA/H/A-29(4)/1516

Zentiva k.s.

Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani

Scope: Possible oral explanation

Action: Possible oral explanation to be held on 18 May 2022 at 09:00

Decentralised Procedure number: SE/H/2098/01–06/DC; SE/H/2099/01–06/DC, notification by the Swedish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting Member States are of the opinion that a positive benefit risk balance is not established under Article 10(3) of Directive 2001/83/EC, as applied, in the absence of bioequivalence and that additional justification is needed to support extrapolation of efficacy and safety to the reference product. Concerns are also raised on the different warning with the reference medicinal product regarding concomitant administration of PPI and /or H2-antagonist and the risk of medication error.

See 10.4

2.4.2. Synchron Research Services – various – EMEA/H/A-31/1515

Various

Referral Rapporteur: Kristina Dunder, Referral Co-Rapporteur: Janet Koenig

Scope: Oral explanation

Action: Oral explanations to be held on 17 May 2022 at 09:00 and 18 May 2022 at 15:30

Article 31 procedure triggered by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium, the Danish Medicines Agency (DKMA), the Finnish Medicines Agency (Fimea), the Medicines Evaluation Board (MEB) in the Netherlands and the Medical Products Agency (MPA) in Sweden concerning the contract research organisation (CRO) Synchron Research Services, located in Ahmedabad, Gujarat, India

See 10.6

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. eptacog beta (activated) - EMEA/H/C/005655

treatment and for the prevention of bleeding

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 24.06.2021.

3.1.2. ertapenem - EMEA/H/C/005815

treatment of bacterial infections and prophylaxis of surgical site infection following elective colorectal surgery

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 24.06.2021.

3.1.3. ganirelix - EMEA/H/C/005641

Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 22.07.2021.

3.1.4. trastuzumab - EMEA/H/C/005880

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

Action: For adoption

3.1.5. budesonide, micronised - Orphan - EMEA/H/C/005653

Calliditas Therapeutics AB; treatment of primary immunoglobulin A (IgA) nephropathy

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022, 27.01.2022. List of Questions adopted on 14.09.2021.

3.1.6. sitagliptin / metformin hydrochloride - EMEA/H/C/005850

treatment of type 2 diabetes mellitus

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 16.09.2021.

3.1.7. sugammadex - EMEA/H/C/005760

Reversal of neuromuscular blockade induced by rocuronium or vecuronium

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 22.07.2021.

3.1.8. trastuzumab - EMEA/H/C/005066

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

3.1.9. eladocagene exuparvovec - Orphan - ATMP - EMEA/H/C/005352

PTC Therapeutics International Limited; treatment of aromatic L-amino aciddecarboxylase (AADC) deficiency

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 05.11.2021, 16.04.2021. List of Questions adopted on 20.05.2020.

3.1.10. olipudase alfa - PRIME - Orphan - EMEA/H/C/004850

Genzyme Europe BV; treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients
disease-modifying enzyme replacement therapy for long-term treatment of non-Central Nervous System

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 20.04.2022. List of Questions adopted on 22.02.2022.

3.1.11. lonafarnib - Orphan - EMEA/H/C/005271

EigerBio Europe Limited; treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022, 16.12.2021, 16.09.2021, 25.02.2021. List of Questions adopted on 23.07.2020.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. vutrisiran - Orphan - EMEA/H/C/005852

Alnylam Netherlands B.V.; treatment of hereditary transthyretin-mediated amyloidosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

3.2.2. mobocertinib - EMEA/H/C/005621

Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.11.2021.

3.2.3. lutetium (177lu) chloride - EMEA/H/C/005859

is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (^{177}Lu) chloride

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.12.2021.

3.2.4. voclosporin - EMEA/H/C/005256

is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.11.2021.

3.2.5. octreotide - Orphan - EMEA/H/C/005826

Amryt Pharmaceuticals DAC; treatment of acromegaly

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.12.2021.

3.2.6. relatlimab / nivolumab - EMEA/H/C/005481

indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents (12 years and older and weighing at least 40 kg)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

3.2.7. pemetrexed - EMEA/H/C/005848

treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.12.2021.

3.2.8. mitapivat - Orphan - EMEA/H/C/005540

Agios Netherlands B.V.; treatment of pyruvate kinase deficiency

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 11.11.2021.

3.2.9. thalidomide - EMEA/H/C/005715

treatment of multiple myeloma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

3.2.10. faricimab - EMEA/H/C/005642

treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.10.2021.

3.2.11. bevacizumab - EMEA/H/C/005534

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer. First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First-line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. nirsevimab - PRIME - EMEA/H/C/005304

Accelerated assessment

Prevention of RSV lower respiratory tract infection. Immunise infants from birth entering their first Respiratory Syncytial Virus (RSV) season for the prevention of RSV lower respiratory tract disease.

Scope: List of questions

Action: For adoption

3.3.2. trastuzumab - EMEA/H/C/005769

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: List of questions

Action: For adoption

3.3.3. paclitaxel - EMEA/H/C/005997

treatment of metastatic breast cancer

Scope: List of questions

Action: For adoption

3.3.4. teclistamab - PRIME - Orphan - EMEA/H/C/005865

Accelerated assessment

Janssen-Cilag International N.V.; treatment of relapsed or refractory multiple myeloma

Scope: List of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. teriparatide - EMEA/H/C/004932

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture

Scope: Letter by the applicant dated 11.05.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in December 2021.

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 28.01.2021.

3.4.2. ranibizumab - EMEA/H/C/005610

treatment of neovascular age-related macular degeneration in adults

Scope: Letter by the applicant dated 05.05.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022, 24.02.2022. List of Questions adopted on 16.09.2021.

3.4.3. ruxolitinib - EMEA/H/C/005843

treatment of non-segmental vitiligo

Scope: Letter by the applicant dated 04.05.2022 requesting an extension to the clock stop to respond to the list of questions adopted in February 2022.

Action: For adoption

List of Questions adopted on 24.02.2022.

3.4.4. ganaxolone - Orphan - EMEA/H/C/005825

Marinus Pharmaceuticals Emerald Limited; treatment of epileptic seizures associated with cyclin dependent kinase-like 5 deficiency disorder (CDD)

Scope: Letter by the applicant dated 09.05.2022 requesting an extension to the clock stop to respond to the list of questions adopted in January 2022.

Action: For adoption

List of Questions adopted on 25.01.2022.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. eptacog alfa (activated) - EMEA/H/C/005547

treatment of bleeding episodes and for the prevention of bleeding

Scope: Withdrawal of marketing authorisation application

Action: For information

List of Questions adopted on 11.11.2021.

3.7.2. autologous glioma tumour cells, inactivated / autologous glioma tumour cell lysates, inactivated / allogeneic glioma tumour cells, inactivated / allogeneic glioma tumour cell lysates, inactivated - Orphan - ATMP - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: Withdrawal of marketing authorisation application

Action: For information

List of Outstanding Issues adopted on 16.07.2021. List of Questions adopted on 22.01.2021.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G

AstraZeneca AB;

Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić

Scope: "Extension application to introduce a new pharmaceutical form, film-coated tablet. A.6 - To change the ATC Code of acalabrutinib from L01XE51 to L01EL02."

Action: For adoption

List of Questions adopted on 24.02.2022.

4.1.2. Rinvoq - upadacitinib - EMEA/H/C/004760/X/0012/G

AbbVie Deutschland GmbH & Co. KG;

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension application to add a new strength (45 mg) of the prolonged-release tablets, grouped with a type II variation (C.I.6.a) to include the treatment of adults with moderately to severely active ulcerative colitis who had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent; as a consequence of the EoI sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 6.0) has also been submitted."

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 27.01.2022.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

No items

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Adcirca - tadalafil - EMEA/H/C/001021/X/0035/G

Eli Lilly Nederland B.V.;

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 6 months to 17 years) based on study 4 (H6D-MC-LVHV [LVHV]) - A 24-week placebo-controlled efficacy and safety study with an open-label long-term extension phase. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The paediatric indication is applicable to the new and all existing presentations. The Package Leaflet and Labelling are updated accordingly. Furthermore, the PI is brought in line with the latest QRD template and editorial changes have been implemented. The RMP (version 9.1) is updated in accordance."

Action: For adoption

4.3.2. Byfavo - remimazolam - EMEA/H/C/005246/X/0002

PAION Netherlands B.V.;

Rapporteur: Bruno Sepodes, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (50 mg powder for concentrate for solution for injection/infusion). The new presentation is indicated to include the intravenous induction and maintenance of general anaesthesia (GA) in adults for Byfavo 50 mg, based on final results from two pivotal trials: Study ONO-2745-05, a phase IIb/III, single-blind, randomised, parallel-group study assessing safety and efficacy in induction and maintenance of anaesthesia in ASA I/II patients (general surgery), and study CNS-7056-022, a phase III, randomized, propofol controlled, parallel group, confirmatory single-blind efficacy and safety trial during induction and maintenance of anaesthesia in ASA III/IV patients.
A new combined version of the SmPC, labelling and Package Leaflet solely for the 50 mg strength and the GA indication is provided accordingly.
Version 1.1 of the RMP has also been submitted.
As part of the application, the MAH also requests an extension of the market protection by one additional year."

Action: For adoption

4.3.3. Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/X/0101/G

ViiV Healthcare B.V.;

Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (5 mg/60 mg/30 mg dispersible tablet). The new presentation is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected children weighing at least 14 kg to less than 25 kg.
This extension application is grouped with a type II variation (C.I.6.a) to include treatment of children weighing at least 25kg for the already approved film-coated tablets for Triumeq (EU/1/14/940/001-002); as a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 19) is updated in accordance."

Action: For adoption

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0003

BeiGene Ireland Ltd;

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) based on results from study BGB-3111-304; an ongoing, international, Phase 3, open-label, multiple-cohort, randomised study designed to evaluate the efficacy of zanubrutinib versus B+R in patients with previously untreated CLL/SLL, and study BGB-3111-305; an ongoing, international Phase 3, open-label, randomized study of zanubrutinib versus ibrutinib with R/R CLL/SLL. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are being updated. The Package Leaflet is updated in accordance. An updated RMP version 1.1 (specific for the proposed indication CLL/SLL) was also submitted. In addition, as part of the application, the MAH requested a 1-year extension of the market protection."

Action: For adoption

5.1.2. Cosentyx - secukinumab - EMEA/H/C/003729/II/0079

Novartis Europharm Limited;

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: "C.I.6 (Extension of indication)
Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy for Cosentyx; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022, 14.10.2021.

5.1.3. Esbriet - pirfenidone - EMEA/H/C/002154/II/0074

Roche Registration GmbH;

Rapporteur: Peter Kiely, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include treatment of 'advanced' idiopathic pulmonary fibrosis (IPF) by the deletion of the current qualifier 'mild to moderate', based on the results from study MA29957; this is a 52-week Phase IIb, multicentre, randomised, double-blind, placebo-controlled clinical trial in IPF patients with advanced lung function impairment (DLco < 40% of predicted) and at high risk of grade 3 pulmonary hypertension, and additional analyses performed on the original pivotal trials for pirfenidone in IPF.
As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. In addition, the MAH took the opportunity to include information in section 4.4 of the SmPC related to the content of sodium per Esbriet capsule and tablet. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted."

Action: For adoption

5.1.4. Exparel liposomal - bupivacaine - EMEA/H/C/004586/II/0005

Pacira Ireland Limited;

Rapporteur: Elita Poplavska, Co-Rapporteur: Margareta Bego, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include children over 6 years old."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021.

5.1.5. Hemlibra - emicizumab - EMEA/H/C/004406/II/0027

Roche Registration GmbH;

Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur:

Amelia Cupelli

Scope: "Extension of indication to include treatment of adult and paediatric patients with haemophilia A without factor VIII (FVIII) inhibitors who have mild or moderate disease for whom prophylaxis is clinically indicated. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC and section 1 of the package leaflet are updated. In addition, section 4.2 is updated to make it clear that the maintenance dose for Hemlibra applies from week 5 of dosing. The PIL is updated accordingly. Version 4.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022.

5.1.6. Ilaris - canakinumab - EMEA/H/C/001109/II/0075

Novartis Europharm Limited;

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with Schnitzler syndrome for Ilaris; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0111

Merck Sharp & Dohme B.V.;

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, stage IIC or stage III melanoma and to include the treatment of adolescents aged 12 years and older with advanced melanoma for Keytruda; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 36.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022, 11.11.2021.

5.1.8. Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G

Teva B.V.;

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age-appropriate presentation in vials; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated

in accordance. Version 12.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021, 12.11.2020.

5.1.9. Nexpovio - selinexor - EMEA/H/C/005127/II/0001/G

Karyopharm Europe GmbH;

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

Scope: "Group of variations including an extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and a quality variation for the addition of a new pack size to align with the dose modification guidance for the new indication. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 6.5 of the SmPC are updated to reflect the new indication and the new pack size. Annex II is updated to reflect the completion of the Specific Obligation. The Labelling and Package Leaflet are amended accordingly. The RMP (v 1.1) is amended consequently."

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022, 16.12.2021, 22.07.2021.

5.1.10. Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0009

Novavax CZ, a.s.;

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include use in adolescents 12 to 17 years of age for Nuvaxovid, based on data from study 2019nCoV-301, a Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to evaluate the efficacy, safety, and immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M Adjuvant in Adult Participants ≥ 18 Years with a Paediatric Expansion in Adolescents (12 to < 18 Years); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

Action: For adoption

5.1.11. Olumiant - baricitinib - EMEA/H/C/004085/II/0029/G

Eli Lilly Nederland B.V.;

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

Scope: "Grouping of the following variations:
C.I.6 - Extension of indication to include treatment of severe alopecia areata in adult

patients for Olumiant; as a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.1 of the RMP has also been submitted.
C.I.11.z - Update of RMP (version 12.1) to change the category 3 study PASS I4V-MC-B011 end of data collection for the Atopic Dermatitis cohort and the subsequent final study report milestone." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022, 16.12.2021.

5.1.12. Ronapreve - casirivimab / imdevimab - EMEA/H/C/005814/II/0002

Roche Registration GmbH;

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of COVID-19 in hospitalised patients in adults and adolescents aged 12 years and older weighing at least 40 kg for Ronapreve; as a consequence, sections 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.13. Veklury - remdesivir - EMEA/H/C/005622/II/0035/G

Gilead Sciences Ireland UC;

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Grouped application of two extensions of indication to include:
- treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment, based on interim results from study GS-US-540-5823; a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Remdesivir in participants from birth to <18 years of age with COVID-19;
- treatment of paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19, based on data from 8 adolescent patients who were included in study GS-US-540-9012, which was initially assessed by the CHMP as part of procedure II/16 (extension of indication to include treatment of adults).
As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet as well as the instructions for healthcare professionals have been updated accordingly. Version 3.2 of the RMP has also been submitted."

Action: For adoption

5.1.14. Xeljanz - tofacitinib - EMEA/H/C/004214/II/0039

Pfizer Europe MA EEIG;

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication to include treatment of active ankylosing spondylitis for Xeljanz prolonged release; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021.

5.1.15. Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046

Kite Pharma EU B.V.;

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, CHMP Coordinators: Jan Mueller-Berghaus and Karin Janssen van Doorn, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) for Yescarta; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.3 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the product information with minor editorial changes." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 18.02.2022.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Eylea - aflibercept - EMEA/H/C/002392/II/0077/G

Bayer AG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault

Scope: Letter by the applicant dated 09.05.2022 requesting an extension to the clock stop to respond to the request for supplementary information adopted in February 2022.

Action: For adoption

Request for supplementary information adopted on 24.02.2022.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006078

detection of PD-L1 protein

Scope: Opinion

Action: For adoption

6.3.2. in vitro diagnostic medical device - EMEA/H/D/006065

In vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and plasma

Scope: Opinion

Action: For adoption

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2s)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide - Orphan - H0005863

Eli Lilly Nederland B.V., For the treatment of mantle cell lymphoma in adults
For the treatment of chronic lymphocytic leukaemia in adults.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0112

GSK Vaccines S.r.l

Rapporteur: Filip Josephson

Scope: "Update of section 5.1 of the SmPC in order to add information based on Real World Evidence (RWE) on vaccination impact and effectiveness from literature references available up to July 2021. The MAH also proposes to remove the existing statement related to paediatric studies in section 5.1 of the SmPC. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC."

Action: For adoption

9.1.2. Caprelsa - vandetanib - EMEA/H/C/002315/II/0043

Genzyme Europe BV

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation. In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021, 24.06.2021, 28.05.2020.

9.1.3. Defitelio - defibrotide - Orphan - EMEA/H/C/002393/II/0056

Gentium S.r.l.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Submission of the final report from study 15-007 listed as a specific obligation in the Annex II of the Product Information. This is a phase 3, randomised, adaptive study (15-007) of defibrotide vs. best supportive care in the prevention of hepatic veno-occlusive disease in adult and paediatric patients undergoing hematopoietic stem cell transplant (HSCT). The RMP version 9 has also been submitted. The MAH has also taken the opportunity to align the PI to the latest QRD template 10.2 which replaces the United Kingdom with United Kingdom (Northern Ireland) in the PIL. In addition, the MAH is correcting the following errata during the linguistic review of the PI: correction of the paragraph number for Regulation (EC) No 726.2004 which was cited incorrectly in Annex II of the French PI and formatting updates to Norwegian and Swedish language PIs."

Action: For adoption

Request for Supplementary Information adopted on 10.03.2022, 28.10.2021, 08.07.2021.

9.1.4. Glubrava - pioglitazone/metformin hydrochloride – EMEA/H/C/000893

Takeda Pharma A/S; treatment of diabetes mellitus type 2

Rapporteur: Peter Kiely, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Rhea Fitzgerald

Scope: Withdrawal of marketing authorisation

Action: For information

9.1.5. Ocaliva - obeticholic acid – Orphan - EMEA/H/C/004093/II/0030

Intercept Pharma International Limited

Rapporteur: Blanca Garcia-Ochoa

Scope: "Update of section 4.3 of the SmPC in order to include contraindication in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event based on the MAH's conclusion that it will not be feasible to establish the safety and efficacy of Ocaliva in these patients from either of the ongoing studies 747-302 and 747-401 listed as Specific Obligations in Annex II. Consequently, dosing instructions for patients with CP-B and CP-C cirrhosis are no longer applicable and section 4.2 has been updated accordingly. In addition, section 4.4 of the SmPC to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions. The MAH also took the opportunity to remove the outdated term "primary biliary cirrhosis" from section 4.1 and to make editorial changes to sections 4.8, 4.9, 5.1 and Annex IIE to improve clarity and correct typographical errors. The Package Leaflet is updated accordingly. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2"

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022, 16.12.2021, 16.09.2021.

9.1.6. Orphacol - cholic acid - EMEA/H/C/001250/II/0044

Laboratoires CTRS

Rapporteur: Anastasia Mountaki

Scope: "Update of sections 4.3 and 4.5 of the SmPC in order to extend the currently existing contra-indication with phenobarbital in order to include primidone based on scientific literature. The Package Leaflet is updated accordingly. In addition, MAH is also taking this opportunity to submit a combined SmPC for both dosages, 50 mg and 250 mg and to introduce editorial changes and update the contact details of the local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

9.1.7. Orphacol - cholic acid - EMEA/H/C/001250/II/0045

Laboratoires CTRS

Rapporteur: Anastasia Mountaki

Scope: "Update of section 4.5 of the SmPC in order update the existing information regarding concomitant use of cholic acid (the active substance of Orphacol) and ursodeoxycholic acid based on scientific literature. The Package Leaflet is updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

9.1.8. Spikevax - elasomeran - EMEA/H/C/005791/II/0057

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: "Update of section 4.2 of the Spikevax SmPC to include a 50 µg booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly."

Action: For adoption

9.1.9. Tygacil – tigecycline – EMEA/H/C/000644/II/0121

Pfizer Europe MA EEIG

Rapporteur: Blanca Garcia-Ochoa

Scope: Update of section 5.1 of the SmPC in order to reflect updated breakpoint tables regarding antimicrobial susceptibility testing (EUCAST). In addition, the MAH is taking the opportunity to update section 4.6 of the SmPC to remove reference to "pharmacodynamic/toxicological" data and update the contact details of the local representatives in the Package Leaflet. In addition, to align the legal prescription status of tigecycline containing products to "Medicinal product subject to medical prescription", section 4.2 of the SmPC of both medicinal products and Annex IIB of Tygecycline Accord needs to be updated accordingly.

Action: For adoption

9.1.10. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0052

AstraZeneca AB

Rapporteur: Sol Ruiz

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a booster dose of Vaxzevria (homologous or heterologous) based on interim immunogenicity and safety data from the pivotal study D7220C00001, a partially double-blinded, randomised, multinational, active-controlled phase II/III clinical study and supportive literature evidence from studies COV001, RHH-001, COV-BOOST and Com-COV studies. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

9.1.11. Zejula - niraparib – Orphan - EMEA/H/C/004249/II/0033

GlaxoSmithKline (Ireland) Limited

Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser

Scope: "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning

and add MDS/AML to the list of adverse drug reactions (ADRs) with frequency common, and update of section 5.1 based on final results from NOVA study (213356); this is a Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer. In addition, the MAH also took this opportunity to update sections 4.4 and 4.6 to update information on contraception based on EMA and CTFG recommendations. The Package Leaflet is updated accordingly. The RMP version 6 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 10.02.2022.

9.1.12. Zynquista – sotagliflozin – EMEA/H/C/004889

Guidehouse Germany GmbH; indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus

Rapporteur: Kristina Dunder, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Martin Huber

Scope: Withdrawal of marketing authorisation

Action: For information

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Daruph and Anafezyn - dasatinib (anhydrous) - EMEA/H/A-29(4)/1516

Zentiva k.s.

Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani

Scope: Possible oral explanation/Opinion

Action: For adoption

Decentralised Procedure number: SE/H/2098/01–06/DC; SE/H/2099/01–06/DC, notification by the Swedish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting Member States are of the opinion that a positive benefit risk balance is not established under Article 10(3) of Directive 2001/83/EC, as applied, in the absence of bioequivalence and that additional justification is needed to support extrapolation of efficacy and safety to the reference product. Concerns are also raised on the different warning with the reference medicinal product regarding concomitant administration of PPI and /or H2-antagonist and the risk of medication error.

See 2.4

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Synchron Research Services – various – EMEA/H/A-31/1515

Various

Referral Rapporteur: Kristina Dunder, Referral Co-Rapporteur: Janet Koenig

Scope: Oral Explanation/Opinion

Action: For adoption

Article 31 procedure triggered by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium, the Danish Medicines Agency (DKMA), the Finnish Medicines Agency (Fimea), the Medicines Evaluation Board (MEB) in the Netherlands and the Medical Products Agency (MPA) in Sweden concerning the contract research organisation (CRO) Synchron Research Services, located in Ahmedabad, Gujarat, India

See 2.4

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

May 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. CHMP membership

None

14.1.2. Vote by proxy

None

14.1.3. Seating plan May 2022 CHMP plenary meeting

Action: for information

14.1.4. Strategic Review and Learning Meetings (SRLM)

CHMP SRLM under the French presidency of the European Union (EU) Council – Paris, 23-24 May 2022

CHMP: Alexandre Moreau

Action: For information

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for May 2022

Action: For adoption

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at May 2022 PDCO

Action: For information

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP May 2022 meeting to CHMP for adoption

Action: For adoption

14.3.2. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 28-29 April 2022.

Action: For adoption

14.3.3. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 02-05 May 2022. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.4. Rheumatology and Immunology Working Party

Chair: Romaldas Maciulaitis

Appointment of an additional member with expertise in the respiratory field

Action: For endorsement

14.3.5. Chair and Vice-Chair election of Working Parties

Election of chair/vice-chair of the following working parties:

- Infectious Diseases WP
- Cardiovascular Working Party

Action: For adoption

14.3.6. Patients` and Consumers` Working Party (PCWP) and Healthcare Professionals` Working Party (HCPWP)

PCWP: Chair: Juan Garcia Burgos

HCPWP: Chair: Juan Garcia Burgos

- DRAFT Agenda - PCWP-HCPWP Joint meeting - June 2022
- Meeting Summary PCWP HCPWP meeting 2-3 March 2022
- DRAFT PCWP_HCPWP Work plan 2022-2025

Action: For information

14.3.7. Oncology European Scientific Expert Group (ESEC)

Appointment of experts

Action: For adoption

14.4. Cooperation within the EU regulatory network

14.4.1. Nitrosamines Multidisciplinary Expert Group (NMEG) on rifampicin

NMEG consultation

Action: For adoption

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

15.1.2. COVID-19 vaccine – EMEA/H/C/006058

immunisation to prevent COVID-19 caused by SARS-CoV-2

Scope: Rolling review 1st interim opinion

Action: For adoption

15.1.3. Updated questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Action: For information

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

28 June 2022
EMA/CHMP/234729/2022 Corr.1[1]

Annex to 16-19 May 2022 CHMP Agenda

Pre-submission and post-authorisations issues

[1] Correction of a scope in section B.6.9

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for
May 2022: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for
May 2022: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Raxone - idebenone -
EMEA/H/C/003834/S/0029, Orphan
Santhera Pharmaceuticals (Deutschland) GmbH,
Rapporteur: John Joseph Borg, PRAC
Rapporteur: Amelia Cupelli
Request for Supplementary Information adopted
on 24.03.2022, 27.01.2022.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Alecensa - alectinib -
EMEA/H/C/004164/R/0039
Roche Registration GmbH, Rapporteur: Filip
Josephson, Co-Rapporteur: Thalia Marie Estrup
Blicher, PRAC Rapporteur: Jana Lukacisinova

Elebrato Ellipta - fluticasone furoate /

umeclidinium / vilanterol -
EMEA/H/C/004781/R/0026
GlaxoSmithKline Trading Services Limited, Duplicate, Duplicate of Trelegy Ellipta, Rapporteur: Peter Kiely, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Annika Folin

Fotivda - tivozanib -
EMEA/H/C/004131/R/0021
EUSA Pharma (Netherlands) B.V., Rapporteur: Bruno Sepodes, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Rugile Pilviniene
Request for Supplementary Information adopted on 24.03.2022.

LUTATHERA - lutetium (177Lu) oxodotreotide -
EMEA/H/C/004123/R/0032, Orphan
Advanced Accelerator Applications, Rapporteur: Janet Koenig, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Adam Przybylkowski
Request for Supplementary Information adopted on 24.03.2022.

Nyxoid - naloxone -
EMEA/H/C/004325/R/0014
Mundipharma Corporation (Ireland) Limited, Rapporteur: Bruno Sepodes, Co-Rapporteur: Elita Poplavska, PRAC Rapporteur: Liana Gross-Martirosyan

Ontruzant - trastuzumab -
EMEA/H/C/004323/R/0040
Samsung Bioepis NL B.V., Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Elita Poplavska, PRAC Rapporteur: Brigitte Keller-Stanislawski

Ritonavir Mylan - ritonavir -
EMEA/H/C/004549/R/0015
Mylan Pharmaceuticals Limited, Generic, Generic of Norvir, Rapporteur: John Joseph Borg, PRAC Rapporteur: Liana Gross-Martirosyan

Tacforius - tacrolimus -
EMEA/H/C/004435/R/0010
Teva B.V., Generic, Generic of Advagraf, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Ronan Grimes

Trelegy Ellipta - fluticasone furoate / umeclidinium / vilanterol -

EMEA/H/C/004363/R/0023
GlaxoSmithKline Trading Services Limited, Rapporteur: Peter Kiely, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Annika Folin

Tremfya - guselkumab - EMEA/H/C/004271/R/0033
Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislawski

VeraSeal - human fibrinogen / human thrombin - EMEA/H/C/004446/R/0018
Instituto Grifols, S.A., Rapporteur: Andrea Laslop, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Amelia Cupelli

Zejula - niraparib - EMEA/H/C/004249/R/0034, Orphan
GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Jan Neuhauser

Zubsolv - buprenorphine / naloxone - EMEA/H/C/004407/R/0019
Accord Healthcare S.L.U., Rapporteur: Peter Kiely, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Martin Huber

B.2.3. Renewals of Conditional Marketing Authorisations

AYVAKYT - avapritinib - EMEA/H/C/005208/R/0017, Orphan
Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

Idefirix - imlifidase - EMEA/H/C/004849/R/0007, Orphan
Hansa Biopharma AB, Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst
Request for Supplementary Information adopted on 22.04.2022.

MINJUVI - tafasitamab - EMEA/H/C/005436/R/0003, Orphan
Incyte Biosciences Distribution B.V., Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Annika Folin

VITRAKVI - larotrectinib - EMEA/H/C/004919/R/0024

Bayer AG, Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene	

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its May 2022 meeting:	
EMEA/H/C/PSUSA/00010029/202110 (dapagliflozin) CAPS: **Edistride** (EMEA/H/C/004161) (dapagliflozin), AstraZeneca AB, Rapporteur: Kristina Dunder **Forxiga** (EMEA/H/C/002322) (dapagliflozin), AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, "05/10/2020 To: 04/10/2021"	
EMEA/H/C/PSUSA/00010733/202109 (galcanezumab) CAPS: **Emgality** (EMEA/H/C/004648) (galcanezumab), Eli Lilly Nederland B.V., Rapporteur: Armando Genazzani, PRAC Rapporteur: Kirsti Villikka, "28/03/2021 To: 27/09/2021"	
EMEA/H/C/PSUSA/00010818/202109 (siponimod) CAPS: **Mayzent** (EMEA/H/C/004712) (siponimod), Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Maria del Pilar Rayon, "26/03/2021 To: 25/09/2021"	

B.4. EPARs / WPARs

Actrapid - insulin human - EMEA/H/W/005779, Article 58 Novo Nordisk A/S, treatment of diabetes mellitus, Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Aduhelm - aducanumab - EMEA/H/C/005558 Biogen Netherlands B.V., Alzheimer's disease, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Filsuvez - birch bark extract -	For information only. Comments can be sent to

EMEA/H/C/005035, Orphan Amryt Pharmaceuticals DAC, treatment to achieve accelerated healing of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients from birth onwards., Known active substance (Article 8(3) of Directive No 2001/83/EC)	the PL in case necessary.
Insulatard - insulin human - EMEA/H/W/005780, Article 58 Novo Nordisk A/S, treatment of diabetes mellitus, Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
LUNSUMIO - mosunetuzumab - EMEA/H/C/005680, Orphan Roche Registration GmbH, refractory follicular lymphoma (FL), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Pirfenidone AET - pirfenidone - EMEA/H/C/005873 Alfred E. Tiefenbacher (GmbH & Co. KG), treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), Generic, Generic of Esbriet, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
SITOIGANAP (WD) - autologous glioma tumour cells, inactivated / autologous glioma tumour cell lysates, inactivated / allogeneic glioma tumour cells, inactivated / allogeneic glioma tumour cell lysates, inactivated - EMEA/H/C/003693, Orphan, ATMP Epitopoietic Research Corporation-Belgium (E.R.C.), treatment of glioma, New active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
Tabrecta - capmatinib - EMEA/H/C/004845 Novartis Europharm Limited, treatment of non-small cell lung cancer (NSCLC), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Yselty - linzagolix choline - EMEA/H/C/005442 ObsEva Ireland Ltd, for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Benepali - etanercept - EMEA/H/C/004007/II/0063/G Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop Opinion adopted on 12.05.2022.	Positive Opinion adopted by consensus on 12.05.2022.
Benlysta - belimumab - EMEA/H/C/002015/II/0104 GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder	
Bimzelx - bimekizumab - EMEA/H/C/005316/II/0003/G UCB Pharma S.A., Rapporteur: Peter Kiely Request for Supplementary Information adopted on 24.03.2022, 13.01.2022.	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0125/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0126/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 26.04.2022.	Positive Opinion adopted by consensus on 26.04.2022.
Darzalex - daratumumab - EMEA/H/C/004077/II/0059/G, Orphan Janssen-Cilag International N.V., Rapporteur: Thalia Marie Estrup Blicher	
Fasturtec - rasburicase - EMEA/H/C/000331/II/0063/G sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 28.04.2022.	Positive Opinion adopted by consensus on 28.04.2022.
Fulphila - pegfilgrastim - EMEA/H/C/004915/II/0029 Viatris Limited, Rapporteur: Martina Weise Request for Supplementary Information adopted on 17.03.2022.	
Hemlibra - emicizumab - EMEA/H/C/004406/II/0029/G	Positive Opinion adopted by consensus on 05.05.2022.

Roche Registration GmbH, Rapporteur: Alexandre Moreau Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 17.03.2022.	
Ilumetri - tildrakizumab - EMEA/H/C/004514/II/0029/G Almirall S.A, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 17.03.2022.	
IMCIVREE - setmelanotide - EMEA/H/C/005089/II/0005/G, Orphan Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn	
Increlex - mecasermin - EMEA/H/C/000704/II/0076 Ipsen Pharma, Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 28.04.2022.	Request for supplementary information adopted with a specific timetable.
Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0036/G, Orphan Alexion Europe SAS, Rapporteur: Karin Janssen van Doorn Request for Supplementary Information adopted on 07.04.2022.	
Lamzede - velmanase alfa - EMEA/H/C/003922/II/0023/G, Orphan Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 03.02.2022.	Positive Opinion adopted by consensus on 05.05.2022.
Lynparza - olaparib - EMEA/H/C/003726/II/0055/G AstraZeneca AB, Rapporteur: Alexandre Moreau	
Ngenla - somatrogon - EMEA/H/C/005633/II/0001/G, Orphan Pfizer Europe MA EEIG, Rapporteur: Peter Kiely	
Oncaspar - pegaspargase - EMEA/H/C/003789/II/0045/G Les Laboratoires Servier, Rapporteur: Alexandre Moreau Opinion adopted on 05.05.2022.	Positive Opinion adopted by consensus on 05.05.2022.
Pedea - ibuprofen - EMEA/H/C/000549/II/0030 Recordati Rare Diseases, Rapporteur: Jayne	

Crowe Request for Supplementary Information adopted on 17.03.2022.	
Perjeta - pertuzumab - EMEA/H/C/002547/II/0063 Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 28.04.2022. Request for Supplementary Information adopted on 17.02.2022.	Positive Opinion adopted by consensus on 28.04.2022.
Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0185 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus	
ReFacto AF - moroctocog alfa - EMEA/H/C/000232/II/0163/G Pfizer Europe MA EEIG, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 05.05.2022.	Positive Opinion adopted by consensus on 05.05.2022.
Rixubis - nonacog gamma - EMEA/H/C/003771/II/0044 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop	
Ruconest - conestat alfa - EMEA/H/C/001223/II/0071 Pharming Group N.V, Rapporteur: Andrea Laslop Opinion adopted on 12.05.2022. Request for Supplementary Information adopted on 17.03.2022.	Positive Opinion adopted by consensus on 12.05.2022.
Senshio - ospemifene - EMEA/H/C/002780/II/0042/G Shionogi B.V., Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 10.02.2022.	
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0053 GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke	
Sivextro - tedizolid phosphate - EMEA/H/C/002846/II/0046 Merck Sharp & Dohme B.V., Rapporteur: Bruno Sepodes	
Spikevax - elasomeran - EMEA/H/C/005791/II/0050	Positive Opinion adopted by consensus on

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 28.04.2022. Request for Supplementary Information adopted on 24.03.2022.	28.04.2022.
Tysabri - natalizumab - EMEA/H/C/000603/II/0132 Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 17.03.2022.	
Voraxaze - glucarpidase - EMEA/H/C/005467/II/0002, Orphan SERB S.A.S., Rapporteur: Ondřej Slanař Opinion adopted on 28.04.2022.	Positive Opinion adopted by consensus on 28.04.2022.
Vyxeos liposomal - daunorubicin / cytarabine - EMEA/H/C/004282/II/0028/G, Orphan Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo Request for Supplementary Information adopted on 07.04.2022.	
Xolair - omalizumab - EMEA/H/C/000606/II/0114 Novartis Europharm Limited, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 24.03.2022, 13.01.2022.	
ZABDENO - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005337/II/0009/G Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege Opinion adopted on 28.04.2022. Request for Supplementary Information adopted on 17.03.2022.	Positive Opinion adopted by consensus on 28.04.2022.
WS2218/G **Advate-** **EMEA/H/C/000520/WS2218/0115/G** **ADYNOVI-** **EMEA/H/C/004195/WS2218/0029/G** Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 17.03.2022.	
WS2225/G **Abseamed-**	Positive Opinion adopted by consensus on

EMEA/H/C/000727/WS2225/0097/G **Binocrit-** **EMEA/H/C/000725/WS2225/0096/G** **Epoetin alfa Hexal-** **EMEA/H/C/000726/WS2225/0096/G** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 17.03.2022.	05.05.2022.
WS2231 **Ambirix-** **EMEA/H/C/000426/WS2231/0121** **Twinrix Adult-** **EMEA/H/C/000112/WS2231/0156** **Twinrix Paediatric-** **EMEA/H/C/000129/WS2231/0157** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke	
WS2232/G **Infanrix hexa-** **EMEA/H/C/000296/WS2232/0314/G** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke	
WS2252 **Prolia-EMEA/H/C/001120/WS2252/0096** **XGEVA-EMEA/H/C/002173/WS2252/0080** Amgen Europe B.V., Lead Rapporteur: Kristina Dunder	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adakveo - crizanlizumab - **EMEA/H/C/004874/II/0007, Orphan** Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, "Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on the results from PK reanalysis. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC."	
Avonex - interferon beta-1a - **EMEA/H/C/000102/II/0192** Biogen Netherlands B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.4 of the SmPC in order to add a new warning regarding the risk of injection site necrosis based on post-marketing experience. The	Request for supplementary information adopted with a specific timetable.

Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 12.05.2022.	
AYVAKYT - avapritinib - EMEA/H/C/005208/II/0014, Orphan Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa, "Submission of the final report from study BLU-285-1101 listed as a Specific Obligation in the Annex II of the Product Information. This is an interventional Phase 1 study, designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of avapritinib administered orally in patients with unresectable GIST or other relapsed or refractory solid tumours. The Annex II is updated accordingly." Request for Supplementary Information adopted on 10.02.2022.	
Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/II/0047 Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, "Update of sections 4.8 and 5.1 of the SmPC in order to include efficacy and safety data for antiretroviral therapy (ART)-naive adults based on final results from interventional studies GS-US-380-1489 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults) and GS-US-380-1490 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults). In addition, the MAH took this opportunity to introduce some minor administrative updates." Request for Supplementary Information adopted on 05.05.2022.	Request for supplementary information adopted with a specific timetable.
Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0101	

UCB Pharma S.A., Rapporteur: Kristina Dunder, "C.I.4: Update of section 4.6 of the SmPC in order to update information on pregnancy based on non-interventional data from the UCB Global Safety Database on prospective Cimzia-exposed pregnancies with known outcomes; the Package Leaflet is updated accordingly."
Request for Supplementary Information adopted on 17.02.2022, 11.11.2021.

Cotellic - cobimetinib - EMEA/H/C/003960/II/0025
Roche Registration GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on final results from study GO29665 (iMATRIX_cobimetinib) which corresponds to study 4 of PIP EMEA-C-001425-PIP01-13-M05. This is a phase I/II, multicentre, open-label, dose-escalation study of the safety, efficacy and pharmacokinetics of cobimetinib in paediatric and young adult patients with previously treated solid tumours. The section 2 of the Package Leaflet is updated accordingly. In addition, final results of the GO29665 study are submitted in line with Article 46 of Regulation (EC) No 1901/2006."
Request for Supplementary Information adopted on 31.03.2022.

Fabrazyme - agalsidase beta - EMEA/H/C/000370/II/0123
Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2 and 6.6 of the SmPC in order to modify administration instructions based on pre-existing data from the clinical trials AGAL-01-002-98, AGAL-005-99, AGAL-008-00, AGAL-02503 and AGAL-016-01 that already serve as the basis for the currently approved SmPC. In addition, section 5.1 of the SmPC is updated in order to add further information on Fabry patients included in the clinical trials. The Package Leaflet is updated accordingly."
Request for Supplementary Information adopted on 10.02.2022.

Fasenra - benralizumab - EMEA/H/C/004433/II/0041
AstraZeneca AB, Rapporteur: Fátima Ventura, "Update of section 5.1 of the SmPC in order to update efficacy information based on the final results from study D3250C00065 (PONENTE);

this is a multicentre, open-label, Phase IIIb efficacy and safety study of benralizumab 30 mg administered subcutaneously to reduce oral corticosteroid use in adult patients with severe eosinophilic asthma on high-dose inhaled corticosteroid plus long-acting β2 agonist and chronic oral corticosteroid therapy. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 27.01.2022.	
IMCIVREE - setmelanotide - EMEA/H/C/005089/II/0006, Orphan Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn, "Submission of the final report from study RM-493-011 "Setmelanotide (RM-493) Treatment Trial in Patients with Rare Genetic Disorders of Obesity". This is a Phase 2, open-label, uncontrolled, non-randomised study with an additional long-term safety extension. The primary objective was to assess changes in body weight within each patient population with rare genetic disorders of obesity (POMC, LEPR, BBS and AS) following 3-months of setmelanotide treatment."	
Jardiance - empagliflozin - EMEA/H/C/002677/II/0062/G Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC with the results of clinical study EMPULSE (1245-0204), a multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initiated in patients hospitalised for acUte heart faiLure (de novo or decompensated chronic HF) who have been StabilisEd (EMPULSE). In addition, the MAH took the opportunity to implement editorial changes in the SmPC." Request for Supplementary Information adopted on 28.04.2022, 10.02.2022.	Request for supplementary information adopted with a specific timetable.
JEMPERLI - dostarlimab - EMEA/H/C/005204/II/0009 GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, "Type II (C.I.4) - To update section 6.6 of the SmPC to include the	Positive Opinion adopted by consensus on 28.04.2022.

requirement to use an in-line filter during finished product administration, to amend the administration equipment compatibilities and to provide additional administration dilution instructions. The Package Leaflet is updated accordingly. In addition, the Applicant took the opportunity to correct a typographical error from SmPC section 5.1 Pharmacodynamic properties." Opinion adopted on 28.04.2022.	
Luminity - perflutren - EMEA/H/C/000654/II/0039 Lantheus EU Limited, Rapporteur: Peter Kiely, "Update of section 4.4 of the SmPC in order to add a new warning on sickle cell anaemia, and update of section 4.8 of the SmPC to include the new ADRs Kounis Syndrome, sickle cell anaemia and vaso-occlusive crisis based on reports in the post-marketing setting. The Package Leaflet is updated accordingly."	
Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0090 Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault, "Submission of the final report from non-interventional PASS Pompe Safety Sub-Registry - AGLU06909/LTS13930. This final study report is submitted to address the assessment report conclusion of the Pompe registry report 2020 (MEA024.15 and MEA025.15 Annual Pompe Registry Report 2020)." Request for Supplementary Information adopted on 05.05.2022.	Request for supplementary information adopted with a specific timetable.
Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0030, Orphan Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of section 4.3 of the SmPC in order to include contraindication in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event based on the MAH's conclusion that it will not be feasible to establish the safety and efficacy of Ocaliva in these patients from either of the ongoing studies 747-302 and 747-401 listed as Specific Obligations in Annex II. Consequently, dosing instructions for patients with CP-B and CP-C cirrhosis are no longer applicable and section 4.2 has been updated accordingly.	See 9.1

In addition, section 4.4 of the SmPC to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions. The MAH also took the opportunity to remove the outdated term "primary biliary cirrhosis" from section 4.1 and to make editorial changes to sections 4.8, 4.9, 5.1 and Annex IIE to improve clarity and correct typographical errors. The Package Leaflet is updated accordingly. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2" Request for Supplementary Information adopted on 24.02.2022, 16.12.2021, 16.09.2021.	
Opsumit - macitentan - EMEA/H/C/002697/II/0043, Orphan Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.2 and 4.4 of the SmPC to remove a sentence and a warning on the limited clinical experience in patients over the age of 75 years, following the recommendation of the EMEA/H/C/PSUSA/00010115/202010 procedure to remove 'Elderly patients' as missing information in the RMP. The Package Leaflet is being updated accordingly. In addition, the MAH took this opportunity to update the Package Leaflet to include a section on Male fertility and align it with the currently approved information in SmPC, sections 4.6 Fertility, pregnancy, and lactation and 5.3 Preclinical safety." Opinion adopted on 28.04.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 28.04.2022.
Orladeyo - berotralstat - EMEA/H/C/005138/II/0006 BioCryst Ireland Limited, Rapporteur: Peter Kiely, "Update of sections 4.4 and 4.5 of the SmPC in order to remove the warning for women of childbearing potential and amend drug-drug interaction information with desogestrel based on final results from study BCX7353-111; this is a phase 1 drug interaction study to evaluate the effects of berotralstat on the pharmacokinetics of a combination oral contraceptive, desogestrel with ethinyl estradiol; the Package Leaflet is updated accordingly."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 12.05.2022.	
Orphacol - cholic acid - EMEA/H/C/001250/II/0044, Orphan Laboratoires CTRS, Rapporteur: Anastasia Mountaki, "Update of sections 4.3 and 4.5 of the SmPC in order to extend the currently existing contra-indication with phenobarbital in order to include primidone based on scientific literature. The Package Leaflet is updated accordingly. In addition, the MAH is also taking this opportunity to submit a combined SmPC for both dosages, 50 mg and 250 mg and to introduce editorial changes and update the contact details of the local representatives in the Package Leaflet." Request for Supplementary Information adopted on 24.03.2022.	See 9.1
Orphacol - cholic acid - EMEA/H/C/001250/II/0045, Orphan Laboratoires CTRS, Rapporteur: Anastasia Mountaki, "Update of section 4.5 of the SmPC in order update the existing information regarding concomitant use of cholic acid (the active substance of Orphacol) and ursodeoxycholic acid based on scientific literature. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 24.03.2022.	See 9.1
Regkirona - regdanvimab - EMEA/H/C/005854/II/0004 Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC to include in vitro neutralization activity of regdanvimab against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern based on report REP-ND22-047."	
Repatha - evolocumab - EMEA/H/C/003766/II/0058 Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, "C.I.4 Update to section 5.1 of the SmPC following the results of interventional study 20160184. It was a double-blind, placebo-controlled, randomized study evaluating the effect of evolocumab on coronary atherosclerotic plaques as assessed by optical coherence tomography (OCT) following 50 weeks of treatment in	Positive Opinion adopted by consensus on 28.04.2022.

subjects with non-ST-elevation acute coronary syndrome (NSTE-ACS) who take maximally tolerated statin therapy." Opinion adopted on 28.04.2022. Request for Supplementary Information adopted on 17.02.2022.	
Revatio - sildenafil - EMEA/H/C/000638/II/0098 Upjohn EESV, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.8 and 5.1 to include long-term safety data in adults for the approved dose, and evidence of safe and effective use in adults in higher than recommended doses, based on study A1481324; a multinational, multicentre randomized, double-blind, parallel-group study in 385 adults with Pulmonary Arterial Hypertension (PAH) undertaken to assess the effects of different dose levels of oral sildenafil on mortality. In addition, the MAH took the opportunity to implement editorial changes in the SmPC." Opinion adopted on 28.04.2022. Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus on 28.04.2022.
Samsca - tolvaptan - EMEA/H/C/000980/II/0046/G Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Armando Genazzani, "Update of section 4.5 of the SmPC in order to include information on the transporter substrates P-glycoprotein, BCRP and OCT1 upon request by PRAC following the assessment of PSUSA/00002994/202105 based on final results from the drug-drug interaction studies 156-201-00233 and 156-201-00234 (to align with the Jinarc PI); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	
Spravato - esketamine - EMEA/H/C/004535/II/0012 Janssen-Cilag International N.V., Rapporteur: Martina Weise, "Update to the SmPC section 4.2 and section 5.1, based on the findings in Chinese subjects from a recently completed efficacy Phase 3 study in adult with treatment-resistant depression." Opinion adopted on 12.05.2022.	Positive Opinion adopted by consensus on 12.05.2022.

Request for Supplementary Information adopted on 10.02.2022.	
Tasigna - nilotinib - EMEA/H/C/000798/II/0115/G Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, "C.I.4: Update of section 4.8 of the SmPC in order to update the ADRs frequency category based on pooled safety data from 13 interventional clinical studies, 5 of which have not been previously assessed (CAMN107A2303 - 120 months data; CAMN107A2404; CAMN107E2401; CAMN107ECN02 and CAMN107EIC01). In addition, the MAH took the opportunity to merge the current 2 SmPCs (one for 150 mg and one for 50 mg/200 mg) into one single SmPC, by including all information from the 150 mg SmPC into the 50 mg/200 mg SmPC; and to implement editorial changes. The Package Leaflet is proposed to be updated accordingly. A.6: Update of nilotinib ATC code based on the last update of the WHO ATC index."	
Tygacil - tigecycline - EMEA/H/C/000644/II/0121 Pfizer Europe MA EEIG, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.1 of the SmPC in order to reflect updated breakpoint tables regarding antimicrobial susceptibility testing (EUCAST). In addition, the MAH is taking the opportunity to update section 4.6 of the SmPC to remove reference to "pharmacodynamic/toxicological" data and update the contact details of the local representatives in the Package Leaflet."	
Vaborem - meropenem / vaborbactam - EMEA/H/C/004669/II/0010/G Menarini International Operations Luxembourg S.A., Rapporteur: Filip Josephson, "A grouped application including 8 type II variations (C.I.4) and 1 type II variation (C.I.13): Update of section 4.5 of the SmPC based on the results of a series of non-clinical drug-drug interaction studies undertaken with vaborbactam or meropenem. The Package Leaflet has been updated accordingly. In addition, the MAH has submitted non-clinical data on the phototoxicity potential of meropenem from a 3T3 neutral red uptake phototoxicity test."	

Request for Supplementary Information adopted on 17.02.2022, 25.11.2021, 11.03.2021.	
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0052 AstraZeneca AB, Rapporteur: Sol Ruiz, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a booster dose of Vaxzevria (homologous or heterologous) based on interim immunogenicity and safety data from the pivotal study D7220C00001, a partially double-blinded, randomised, multinational, active-controlled phase II/III clinical study and supportive literature evidence from studies COV001, RHH-001, COV-BOOST and Com-COV studies. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information." Request for Supplementary Information adopted on 22.04.2022.	See 9.1
Veltassa - patiromer - EMEA/H/C/004180/II/0029 Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Update of sections 4.2 and 4.5 of the SmPC in order to introduce new drug-drug interaction information based on results from four in vitro studies: RLY-TR-0174, titled "In Vitro Evaluation of Potential RLY5016S and Immunosuppressant Drug-Drug Interactions"; RLY-TR-0184 (titled "In Vitro Evaluation of Potential Drug-Drug Interactions Between Patiromer and Sevelamer Hydrochloride"); "In Vitro Evaluation of Drug-Drug Interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS" and "Drug-drug interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS in a simulated GI tract passage study". The Package Leaflet is updated accordingly."	
Vidaza - azacitidine - EMEA/H/C/000978/II/0057 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, "Update of section 4.2 of the SmPC in order to include a statement advising health care professionals not to interchange azacitidine formulations (injectable	Positive Opinion adopted by consensus on 28.04.2022.

versus oral), and update section 4.6 of the SmPC to revise the recommended duration of contraception use for women and men. The Package Leaflet is updated accordingly." Opinion adopted on 28.04.2022.	
VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0054, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Martina Weise, "Submission of the final report from study SHP-GCB-402: a multicentre, open-label, single-arm, phase 4 study designed to prospectively evaluate the effects of VPRIV on bone-related pathology in treatment-naïve subjects with type 1 Gaucher disease." Request for Supplementary Information adopted on 28.04.2022.	Request for supplementary information adopted with a specific timetable.
Vyxeos liposomal - daunorubicin / cytarabine - EMEA/H/C/004282/II/0030, Orphan Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo, "Update of sections 4.2, 4.4 and 5.2 of the SmPC to amend information and delete the existing warning for patients with renal impairment based on the final results from study CPX351-102 (PMR2): a phase 1, open-label, PK and safety study to evaluate the potential impact of renal impairment on the pharmacokinetics and safety of CPX-351 (Daunorubicin and Cytarabine) liposome for injection treatment in adult patients with hematologic malignancies."	
WS2244 Nuwiq-EMEA/H/C/002813/WS2244/0048 Vihuma-EMEA/H/C/004459/WS2244/0030 Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and efficacy data based on the final CSR from the category 3 study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A. Further, upon request by the CHMP following the assessment of study GENA-05 (P46 013 and P46 014), the MAH is updating the numbers of evaluated subjects in SmPC section 4.8 and is	Request for supplementary information adopted with a specific timetable.

removing of the sentence "A prospective open-label clinical study in PUPs with severe haemophilia A (<1% FVIII:C) is ongoing" in section 5.1 of the SmPC. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 05.05.2022.	
WS2250 **Prezista-** **EMEA/H/C/000707/WS2250/0116** **Rezolsta-** **EMEA/H/C/002819/WS2250/0046** **Symtuza-** **EMEA/H/C/004391/WS2250/0043** Janssen-Cilag International N.V., Lead Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.3 and 4.5 of the SmPC in order to update the safety information based on final results from study TMC114FD1HTX1002; this is an interventional phase 1, 2-Panel, Fixed-Sequence, Open-Label Single-Center Study to Assess the Effect of Single and Multiple Doses of Darunavir in Combination with Cobicistat or Ritonavir on the Pharmacokinetics of Single Dose Dabigatran Etexilate in Healthy Participants. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes in order to update the contact details of the local representatives in the Package Leaflet."	
WS2253 **Eucreas-** **EMEA/H/C/000807/WS2253/0096** **Galvus-EMEA/H/C/000771/WS2253/0076** **Icandra-** **EMEA/H/C/001050/WS2253/0100** **Jalra-EMEA/H/C/001048/WS2253/0078** **Xiliarx-EMEA/H/C/001051/WS2253/0077** **Zomarist-** **EMEA/H/C/001049/WS2253/0098** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, "Update of section 4.8 of the SmPC in order to add the new ADRs 'cutaneous vasculitis'." Request for Supplementary Information adopted on 05.05.2022.	Request for supplementary information adopted with a specific timetable.

B.5.3. CHMP-PRAC assessed procedures

Alecensa - alectinib - EMEA/H/C/004164/II/0037/G

Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Jana Lukacisinova, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to add a new warning, dose modification advice and description of the known ADR haemolytic anaemia based on an updated Drug Safety Report; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial updates in the Maltese and Romanian product information. Moreover, the ATC code for alectinib is being updated from L01XE36 to L01ED03."
Request for Supplementary Information adopted on 27.01.2022.

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0002

Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.5, 4.8 and 5.1 of the SmPC to add information regarding the co-administration of Apexxnar with seasonal quadrivalent influenza vaccine (QIV) based on final study results from study B7471004, "A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20 valent Pneumococcal Conjugate Vaccine (20vPnC) When Coadministered with Seasonal Inactivated Influenza Vaccine (SIIV) in Adults ≥65 Years of Age." listed as a category 3 study in the RMP.
The Package Leaflet is updated accordingly.
The updated RMP version 1.1 has also been submitted."

ASPAVELI - pegcetacoplan - EMEA/H/C/005553/II/0002, Orphan

Swedish Orphan Biovitrum AB (publ), Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kimmo Jaakkola, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on final results from study APL2-302 (Pegasus) listed as a category 3 study in the RMP; this is a global, Phase 3, prospective, randomised, multicentre, open-label, active-comparator–controlled study in 80 subjects. The

objective was to confirm treatment efficacy and safety of pegcetacoplan monotherapy for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The submission of this study addresses MEA 001.The Package Leaflet is updated accordingly. The RMP version 0.5 has also been submitted." Request for Supplementary Information adopted on 24.03.2022.	
Caprelsa - vandetanib - EMEA/H/C/002315/II/0043 Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/ metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation. In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information." Request for Supplementary Information adopted on 16.12.2021, 24.06.2021, 28.05.2020.	See 9.1
Defitelio - defibrotide - EMEA/H/C/002393/II/0056, Orphan Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Submission of the final report from study 15-007 listed as a specific obligation in the Annex II of the Product Information. This is a phase 3, randomised, adaptive study (15-007) of Defibrotide vs. best supportive care in the prevention of hepatic venoocclusive disease in adult and paediatric patients undergoing hematopoietic stem cell transplant (HSCT). The RMP version 9 has also been submitted. The MAH has also taken the opportunity to align the PI to the latest QRD template 10.2 which replaces the United Kingdom with United	See 9.1

Kingdom (Northern Ireland) in the PIL. In addition, the MAH is correcting the following errata during the linguistic review of the PI: correction of the paragraph number for Regulation (EC) No 726.2004 which was cited incorrectly in Annex II of the French PI and formatting updates to Norwegian and Swedish language PIs." Request for Supplementary Information adopted on 10.03.2022, 28.10.2021, 08.07.2021.	
Deltyba - delamanid - EMEA/H/C/002552/II/0053, Orphan Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs table) following the development of a improved methodology to identify relevant ADRs likely attributable to delamanid. The section 4 of the Package Leaflet is updated accordingly. The RMP version 3.6 has also been submitted." Request for Supplementary Information adopted on 05.05.2022, 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Dexdor - dexmedetomidine - EMEA/H/C/002268/II/0035 Orion Corporation, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.4 of the SmPC and PL section 2 in order to add a new warning on increased mortality in ICU patients ≤ 65 years old, based on results from study SPICE III (randomised controlled trial) and following the assessment of the post-authorisation measure LEG 16.4. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 9, a proposed DHPC and communication plan have also been submitted." Request for Supplementary Information adopted on 24.03.2022.	
Enbrel - etanercept - EMEA/H/C/000262/II/0246 Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of section 5.1 of the Summary of product characteristics (SmPC) in order to update clinical information based on final results obtained from the clinical paediatric	Positive Opinion adopted by consensus on 05.05.2022.

study B1801023 (CLIPPER 2). Also, the Risk management plan (RMP) was brought up to date with version 7.6." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 13.01.2022.	
GIVLAARI - givosiran - EMEA/H/C/004775/II/0006, Orphan Alnylam Netherlands B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Update of SmPC section 4.8 to add 'blood homocysteine increase' as a new ADR with the frequency 'common' and SmPC section 4.4 to add a related warning. The Package Leaflet is being updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representatives for Malta and Cyprus in the Package Leaflet. An updated RMP version 1.4 was agreed during the procedure: consequences of blood homocysteine increase is being added as a new important potential risk, the clinical and post-marketing exposure is being updated and the due dates for ALN-AS1-002 and ALN-AS1-003 final study reports are being revised." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 10.03.2022, 13.01.2022, 28.10.2021, 02.09.2021.	Positive Opinion adopted by consensus on 05.05.2022.
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0069 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of the SmPC section 4.4 to include information on fatal and serious cardiac arrythmias and cardiac failure, relevant warnings and periodical monitoring of patients- following a safety assessment for increased risk of sudden death/cardiac death with the use of ibrutinib. Section 2 of the PL has been updated accordingly. Typographical errors have been corrected throughout the PI. The revised RMP version 11 has been submitted." Request for Supplementary Information adopted on 27.01.2022.	
Jorveza - budesonide - EMEA/H/C/004655/II/0015, Orphan Dr. Falk Pharma GmbH, Rapporteur: Martina	

Weise, PRAC Rapporteur: Zane Neikena, "Update of section 4.8 of the SmPC in order to update the list of adverse reactions based on final results from the long-term maintenance study BUL-2/EER; this is a double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitis. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 3.0 has also been submitted. The MAH also submitted the final report of study BUL-6/BIO, which was previously assessed within the scope of extension EMEA/H/C/004655/X/0007/G as applicant's response to CHMP Day 120 List of Questions."	
Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0017/G, Orphan Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "C.I.4 Update of section 5.3 of the SmPC in order to update the non-clinical information based on final results from a 2-year oral carcinogenicity study in rats (VX-445-TX-015) evaluating the carcinogenic potential of up to 10 mg/kg/day of elexacaftor. An updated RMP (version 6.0) has also been submitted to include the completion of the 2-year carcinogenicity study in rats as well as to update the post-market pregnancy safety information collection form following EMEA/H/C/WS2048. C.I.13 To submit the final report of Tezacaftor Juvenile Toxicity study (VX-661-TX-038)." Request for Supplementary Information adopted on 05.05.2022, 10.02.2022.	Request for supplementary information adopted with a specific timetable.
Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/II/0024, Orphan Pfizer Europe MA EEIG, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of sections 4.8, 5.1 and 5.2 of the SmPC based on	

the final results from study B176103; this is a single-arm, open-label, phase 4 study evaluating the QT interval, pharmacokinetics, and safety of gemtuzumab ozogamicin as a single-agent regimen in patients with relapsed or refractory CD33-positive Acute Myeloid Leukaemia. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to introduce some editorial changes in the product information." Request for Supplementary Information adopted on 18.03.2022.	
Neofordex - dexamethasone - EMEA/H/C/004071/II/0017/G Laboratoires CTRS, Rapporteur: Ondřej Slanař, PRAC Rapporteur: Tiphaine Vaillant‟1. C.I.11.z (Type IB): To update the RMP for Neofordex to version 4.3 with a completion of category 3 activity 'Removal of the score line for sub-division of the 40 mg tablet, and consequent deletion of the 20 mg posology' and to include the Direct Healthcare Professional Communication (DHPC); " Request for Supplementary Information adopted on 05.05.2022.	Request for supplementary information adopted with a specific timetable.
Pemazyre - pemigatinib - EMEA/H/C/005266/II/0005, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study INCB054828 (FIGHT-202) listed as a specific obligation in the Annex II (SOB/002); this is a phase 2 study investigating the efficacy and safety of pemigatinib in adults with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy. The Annex II has been updated accordingly. RMP version 2.0 has also been submitted." Request for Supplementary Information adopted on 24.03.2022.	
Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0006 Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Submission of the final report	Positive Opinion adopted by consensus on 05.05.2022.

from study MVT-601-035 listed as a category 3 study in the RMP. This is an international phase III double-blind, placebo-controlled, randomised withdrawal study of relugolix co-administered with estradiol and norethisterone in women with heavy menstrual bleeding associated with uterine fibroids to evaluate the efficacy and safety of long-term use of this medicinal product. The RMP version 1.0 has also been submitted." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 10.03.2022.	
Uptravi - selexipag - EMEA/H/C/003774/II/0034 Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Nathalie Gault, "Update of section 4.8 of the SmPC to add 'dyspepsia' as a new ADR with frequency 'common', and to include further information on the frequency of 'dyspepsia' and 'anaemia' specific to initial 2-step triple combination therapy, based on the Studies AC-065A308 (TRITON) and AC-065A404 (TRACE). AC-065A308 (TRITON) study was a randomized, double-blind, placebo-controlled, parallel-group, Phase 3b, efficacy and safety study comparing triple oral combination therapy (selexipag, macitentan, tadalafil) with double oral combination therapy (placebo, macitentan, tadalafil) in newly diagnosed, treatment-naïve participants with PAH. The AC-065A404 (TRACE) study was a randomized, double-blind, placebo-controlled, parallel-group, exploratory Phase 4 study in participants with PAH to assess the effect of selexipag on daily life physical activity and participant's self-reported symptoms and their impacts. The package leaflet is updated accordingly. A revised RMP version 9.2 was provided as part of the application." Request for Supplementary Information adopted on 02.12.2021.	
XOSPATA - gilteritinib - EMEA/H/C/004752/II/0007, Orphan Astellas Pharma Europe B.V., Rapporteur: Ingrid Wang, PRAC Rapporteur: Martin Huber, "Submission of the report of an integrated analysis to demonstrate the safety of long-term treatment with gilteritinib when all patients	Positive Opinion adopted by consensus on 05.05.2022.

enrolled in studies 2215-CL-0101, 2215-CL-0102 and 2215-CL-0301 have completed at least 3 years of treatment with gilteritinib or have withdrawn prior to completing at least 3 years of treatment. The studies refer to: 1) study 2215-CL-0101: a phase 1/2 open-label, dose escalation study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASP2215 (gilteritinib) in patients with relapsed or refractory acute myeloid leukaemia (AML); 2) study 2215-CL-0102: a phase 1 open-label, dose escalation study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASP2215 in Japanese patients with relapsed or refractory AML; 3) study 2215-CL-0301: a phase 3 open-label, multicentre, randomized study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory AML with FMS-like tyrosine kinase 3 (FLT3) mutation. The RMP (version 2.0) is updated in order to address the missing information regarding the safety of Xospata (gilteritinib)." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 10.02.2022.	
Zejula - niraparib - EMEA/H/C/004249/II/0033, Orphan GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning and add MDS/AML to the list of adverse drug reactions (ADRs) with frequency common, and update of section 5.1 based on final results from NOVA study (213356); this is a Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer. In addition, the MAH took this opportunity to update section 4.4 and 4.6 to update information on contraception based on EMA and CTFG recommendations. The Package Leaflet is updated accordingly. The RMP version 6 has also been submitted." Request for Supplementary Information adopted on 10.02.2022.	See 9.1
Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/II/0034	Positive Opinion adopted by consensus on 05.05.2022.

Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the final report from study MK-5172-017, listed as a category 3 study in the RMP. This is a Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with Zepatier in a Prior Clinical Trial. The submission of the study report addresses MEA 002.1. The RMP version 5.1 has also been submitted." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 07.04.2022.	

B.5.4. PRAC assessed procedures

PRAC Led **Adasuve - loxapine - EMEA/H/C/002400/II/0033** Ferrer Internacional s.a., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update safety information on Bronchospasm based on final results from study AMDC-204-401 EU PASS (assessed in procedure EMEA/H/C/0002400/II/0032): Post-authorisation Observational Study to Evaluate the Safety of ADASUVE (Staccato loxapine for inhalation) in Agitated Persons in Routine Clinical Care, a category 3 study in the RMP; the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 05.05.2022, 02.12.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Enbrel - etanercept - EMEA/H/C/000262/II/0244** Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13: Submission of the final report from study B1801310 (BIKER), listed as a category 3 study in the RMP. This is an observational Post-Authorisation Safety	Positive Opinion adopted by consensus on 05.05.2022.

Study (PASS) of Etanercept and Methotrexate in the treatment of Juvenile Idiopathic Arthritis (JIA) using data obtained from participants in the German Biologics JIA Registry (BIKER) to monitor long-term safety and effectiveness of etanercept in the treatment of JIA in regular clinical practice." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 10.02.2022, 02.09.2021.	
PRAC Led **HEPLISAV B - hepatitis b surface antigen - EMEA/H/C/005063/II/0014** Dynavax GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study (HBV25) listed as a category 3 PASS study in the RMP. This is a post-marketing observational surveillance study comparing the occurrence of Acute Myocardial Infarction (AMI) in recipients of HEPLISAV-B with recipients of another hepatitis B vaccine. As a consequence, the RMP version 1.2 has also been submitted, in which the MAH proposed the removal of AMI as an important potential risk from the list of safety concerns." Opinion adopted on 05.05.2022.	Positive Opinion adopted by consensus on 05.05.2022
PRAC Led **Lemtrada - alemtuzumab - EMEA/H/C/003718/II/0041** Sanofi Belgium, Duplicate, Duplicate of Lemtrada (WD), Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an updated RMP version 10.0 in order to include the new important identified risk "Autoimmune Encephalitis" and to introduce changes in accordance to the rapporteurs' requests received as part of procedure EMEA/H/C/003718/II/0038." Request for Supplementary Information adopted on 05.05.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Otezla - apremilast - EMEA/H/C/003746/II/0038** Amgen Europe B.V., Rapporteur: Peter Kiely, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP	Positive Opinion adopted by consensus on 05.05.2022.

liaison: Maria Concepcion Prieto Yerro, "C.I.13 - Submission of the final study report (CSR) from PsOBest Registry, listed as a category 3 study in the RMP. This is an observational study to assess the long-term safety and effectiveness of apremilast in routine clinical practice in Germany. The RMP version 14.0 has also been submitted." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 30.09.2021.	
PRAC Led **Remicade - infliximab - EMEA/H/C/000240/II/0231** Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report of the Remicade AntiRheumatic Therapy in Sweden (ARTIS) registry study. The ARTIS registry study was performed to fulfil a post-authorisation measure in the RMP for Remicade. The updated RMP v20.1. has also been submitted, including revisions agreed in previous procedures." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 05.05.2022.
PRAC Led **Uptravi - selexipag - EMEA/H/C/003774/II/0035** Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Submission of an updated RMP version 9.3 in order to include the amendment of the ongoing EXPOSURE study protocol, to add the EXTRACT study (67896049PAH0002) as an additional pharmacovigilance activity (PASS) and to include the update of the PRAC-approved EDUCATE PASS protocol (assessed in EMEA/H/C/003774/MEA/003.4)." Request for Supplementary Information adopted on 05.05.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Vargatef - nintedanib - EMEA/H/C/002569/II/0044** Boehringer Ingelheim International GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Georgia Gkegka, PRAC-CHMP	Request for supplementary information adopted with a specific timetable.

liaison: Konstantina Alexopoulou, "Submission of an updated RMP version 10.0 in order to remove safety concerns that were classified as important identified risks, important potential risks and missing information, based on cumulative post-marketing experience. The MAH is also proposing an update of the ATC code, an update of post-marketing exposure, the removal of adverse event follow-up forms and an update of search strategies." Request for Supplementary Information adopted on 05.05.2022, 10.02.2022.	
PRAC Led **VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0049, Orphan** Takeda Pharmaceuticals International AG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of final physician data study results for PASS study "Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals and Patient/Caregivers to Assess their Knowledge and Attitudes on Prescribing and Home Administration Conditions of Velaglucerase Alpha (VPRIV) in 6 European Countries" (EUPASS 14255)" Request for Supplementary Information adopted on 05.05.2022, 02.12.2021, 08.07.2021, 11.02.2021, 26.11.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Zessly - infliximab - EMEA/H/C/004647/II/0020** Sandoz GmbH, Rapporteur: Eva Skovlund, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the updated RMP version 3.0 to remove the RABBIT registry as an additional pharmacovigilance activity in alignment with the updated version of the reference product Remicade RMP (v19) and to remove the BADBIR registry as an additional pharmacovigilance activity." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 05.05.2022.
PRAC Led **WS2151 Aflunov- EMEA/H/C/002094/WS2151/0071**	Positive Opinion adopted by consensus on 05.05.2022.

Foclivia-
EMEA/H/C/001208/WS2151/0068
Seqirus S.r.l, Lead Rapporteur: Armando Genazzani, Lead PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Update of the RMP (part I, II, III, IV, V and VI) for AFLUNOV and FOCLIVIA in order to align the list of safety concerns for the products. The modules 'Epidemiology of the indication and target population' and 'Identified and potential risks' and the section of missing information are updated. Some potential risks have been reclassified following the definition as per GVP Module V rev.2. RMP version 4.0 was approved with this variation."
Opinion adopted on 05.05.2022.
Request for Supplementary Information adopted on 10.02.2022, 28.10.2021.

B.5.5. CHMP-CAT assessed procedures

Imlygic - talimogene laherparepvec -
EMEA/H/C/002771/II/0050, ATMP
Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo

Imlygic - talimogene laherparepvec -
EMEA/H/C/002771/II/0052/G, ATMP
Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo

Kymriah - tisagenlecleucel -
EMEA/H/C/004090/II/0053, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, "Submission of the final report from study CCTL019H2301 (BELINDA) listed as an obligation in the Annex II of the Product Information. This is a randomized open-label parallel-group multicentre Phase III trial to evaluate the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory B-cell aggressive NHL after failure of rituximab and anthracycline containing first-line immune-chemotherapy. The Annex II is updated accordingly."

Zolgensma - onasemnogene abeparvovec -
EMEA/H/C/004750/II/0020/G, Orphan,

ATMP
Novartis Gene Therapies EU Limited,
Rapporteur: Carla Herberts, CHMP Coordinator:
Johann Lodewijk Hillege
Request for Supplementary Information adopted
on 18.03.2022, 10.12.2021.

Zolgensma - onasemnogene abeparvovec -
EMEA/H/C/004750/II/0024, Orphan,
ATMP
Novartis Gene Therapies EU Limited,
Rapporteur: Carla Herberts, CHMP Coordinator:
Johann Lodewijk Hillege,
Request for Supplementary Information adopted
on 18.03.2022.

WS2247
Tecartus-
EMEA/H/C/005102/WS2247/0020
Yescarta-
EMEA/H/C/004480/WS2247/0050
Kite Pharma EU B.V., Lead Rapporteur: Jan
Mueller-Berghaus, CHMP Coordinator: Jan
Mueller-Berghaus

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

PRAC Led
Imlygic - talimogene laherparepvec -
EMEA/H/C/002771/II/0051, ATMP
Amgen Europe B.V., CHMP Coordinator:
Johanna Lähteenvuo, PRAC Rapporteur: Brigitte
Keller-Stanislawski, PRAC-CHMP liaison: Jan
Mueller-Berghaus, "Submission of the final
report from study 20180062; "Observational
Research Study Report (ORSR)" listed as a
category 3 study in the RMP. This is a
multinational, non-interventional, cross-
sectional survey study for the Patients aged ≥
18 years who have received IMLYGIC at least
once in the 3 months prior to completing the
survey to evaluate the effectiveness of the
patient-directed aRMMS. The primary objective
of this study is to evaluate patients' knowledge
levels of the key messages included in the
IMLYGIC Patient Safety Brochure among
patients who receive IMLYGIC."

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2136 **Esperoct-** **EMEA/H/C/004883/WS2136/0009** **NovoEight-** **EMEA/H/C/002719/WS2136/0039** Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 28.04.2022. Request for Supplementary Information adopted on 03.02.2022.	Positive Opinion adopted by consensus on 28.04.2022.
WS2227 **Esperoct-** **EMEA/H/C/004883/WS2227/0011** **NovoEight-** **EMEA/H/C/002719/WS2227/0040** Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 28.04.2022.	Request for supplementary information adopted with a specific timetable.
WS2229/G **Efficib-** **EMEA/H/C/000896/WS2229/0105/G** **Janumet-** **EMEA/H/C/000861/WS2229/0104/G** **Ristfor-** **EMEA/H/C/001235/WS2229/0092/G** **Velmetia-** **EMEA/H/C/000862/WS2229/0108/G** Merck Sharp & Dohme B.V., Lead Rapporteur: Johann Lodewijk Hillege	
WS2239/G **Hexacima-** **EMEA/H/C/002702/WS2239/0128/G** **Hexyon-** **EMEA/H/C/002796/WS2239/0132/G** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus	
WS2240 **HyQvia-EMEA/H/C/002491/WS2240/0077** **Kiovig-EMEA/H/C/000628/WS2240/0116** Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus	
WS2273 **Rixathon-** **EMEA/H/C/003903/WS2273/0055** **Riximyo-**	

EMEA/H/C/004729/WS2273/0056 Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus, "To update section 6.6 of the SmPC and section 2 of the PL to align the wording with the originator Mabthera, following finalisation of procedure EMEA/H/C/000165/II/0185/G. In addition, the marketing authorisation holder has taken the opportunity to implement minor editorial changes in the PI."

B.5.9. Information on withdrawn type II variation / WS procedure

Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0027 Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 17.03.2022. Withdrawal request submitted on 26.04.2022.	The MAH withdrew the procedure on 26.04.2022.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Spikevax - elasomeran - EMEA/H/C/005791/X/0064 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, "Extension application to add a new strength of 0.10 mg/ml in a 5-dose vial."
Spikevax - elasomeran - EMEA/H/C/005791/X/0065 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, "Extension application to add a new strength of 0.10 mg/ml in pre-filled syringe."

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

in vitro diagnostic medical device - EMEA/H/D/006065 In-vitro quantitative determination of anti-

Müllerian hormone (AMH) in human serum and plasma
Request for Supplementary Information adopted on 22.04.2022, 24.03.2022.

maralixibat - EMEA/H/C/005857, Orphan
Mirum Pharmaceuticals International B.V., Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older
List of Questions adopted on 27.01.2022.

tirzepatide - EMEA/H/C/005620
treatment of adults with type 2 diabetes mellitus
List of Questions adopted on 24.02.2022.

iodine (131I) omburtamab - EMEA/H/C/005499, Orphan
Y-Mabs Therapeutics A/S, treatment of neuroblastoma
List of Questions adopted on 16.09.2021.

in vitro diagnostic medical device - EMEA/H/D/006078
detection of PD-L1 protein
Request for Supplementary Information adopted on 22.04.2022.

teriflunomide - EMEA/H/C/005962
treatment of multiple sclerosis (MS)
List of Questions adopted on 27.01.2022.

teriparatide - EMEA/H/C/005793
treatment of osteoporosis
List of Questions adopted on 20.05.2021.

ranibizumab - EMEA/H/C/005617
treatment of neovascular age-related macular degeneration (AMD)
List of Questions adopted on 27.01.2022.

B.6.4. Annual Re-assessments: timetables for adoption

Chenodeoxycholic acid Leadiant - chenodeoxycholic acid - EMEA/H/C/004061/S/0020, Orphan
Leadiant GmbH, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Adam Przybylkowski

DECTOVA - zanamivir - EMEA/H/C/004102/S/0013
GlaxoSmithKline Trading Services Limited,

Rapporteur: Ingrid Wang, PRAC Rapporteur: Ulla Wändel Liminga

Elaprase - idursulfase - EMEA/H/C/000700/S/0099
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Evoltra - clofarabine - EMEA/H/C/000613/S/0076
Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Firdapse - amifampridine - EMEA/H/C/001032/S/0073
SERB SA, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Adakveo - crizanlizumab - EMEA/H/C/004874/R/0008, Orphan
Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/R/0033
Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst

Alkindi - hydrocortisone - EMEA/H/C/004416/R/0014
Diurnal Europe BV, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Annika Folin

Fasenra - benralizumab - EMEA/H/C/004433/R/0044
AstraZeneca AB, Rapporteur: Fátima Ventura, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: David Olsen

Hemlibra - emicizumab - EMEA/H/C/004406/R/0032
Roche Registration GmbH, Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Amelia Cupelli

Intrarosa - prasterone - EMEA/H/C/004138/R/0022

Endoceutics S.A., Rapporteur: Jean-Michel Race, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Menno van der Elst

Jorveza - budesonide - EMEA/H/C/004655/R/0016, Orphan
Dr. Falk Pharma GmbH, Rapporteur: Martina Weise, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Zane Neikena

MVASI - bevacizumab - EMEA/H/C/004728/R/0025
Amgen Technology (Ireland) Unlimited Company, Duplicate, Duplicate of KYOMARC, Rapporteur: Eva Skovlund, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Anette Kirstine Stark

Ocrevus - ocrelizumab - EMEA/H/C/004043/R/0033
Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Brigitte Keller-Stanislawski

Ozempic - semaglutide - EMEA/H/C/004174/R/0030
Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Ebru Karakoc Madsen, PRAC Rapporteur: Annika Folin

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Ceprotin - human protein C - EMEA/H/C/000334/II/0127
Takeda Manufacturing Austria AG, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include long-term prophylaxis (deletion of wording 'short-term' and currently listed conditions) of purpura fulminans and coumarin induced skin necrosis in patients with severe congenital protein C deficiency, based on a re-analysis of long-term prophylaxis data from the pivotal study 400101; a phase 2/3 clinical study undertaken to evaluate PK, safety and efficacy of CEPROTIN in patients with severe congenital PC deficiency for the treatment of acute

thrombotic episodes, for short-term thromboembolic prophylaxis and for long-term prophylactic treatment. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC are updated and the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 2.0 of the RMP has also been submitted. ”

Dupixent - dupilumab - EMEA/H/C/004390/II/0062

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola, “Extension of indication to include treatment of eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy, based on the pivotal study R668-EE-1774. This is an ongoing phase 3, randomized, double-blind, placebo-controlled, 3-part (A, B, C) safety and efficacy study with an initial 24-week treatment period in adults (≥18 years of age) and adolescents (≥12 to <18 years of age) with EoE, and which includes an extended treatment period to a total of 52 weeks. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
Version 8.0 of the RMP has also been submitted.”

Dupixent - dupilumab - EMEA/H/C/004390/II/0063

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola, “Extension of indication to include treatment of adults with moderate to severe prurigo nodularis (PN) who are candidates for systemic therapy, based on results from studies EFC16459 and EFC16460 (PRIME and PRIME2); these are two phase 3, 24-week, randomized, double-blind, placebo-controlled, multi-centre, parallel group studies undertaken to evaluate the efficacy and safety of dupilumab in patients 18 years of age and older with moderate to severe PN, who are inadequately controlled on topical prescription

therapies or when those therapies are not advisable. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. As part of this application, the MAH is also requesting a 1-year extension of the market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0045 AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: David Olsen, "Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from study D419CC00002 (HIMALAYA); This was a randomized, open-label, multi-centre phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 6.1 of the RMP has also been submitted."	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0046 AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen, "Extension of indication to include IMFINZI in combination with chemotherapy for the treatment of adults with locally advanced or metastatic biliary tract cancer (BTC), based on the second interim analysis from the ongoing pivotal study D933AC00001 (TOPAZ-1); a phase III randomized, double-blind, placebo-controlled, multi-regional, international study conducted to assess the efficacy and safety of durvalumab in combination with the current standard of care Gemcitabine/Cisplatin for the first-line treatment of patients with locally advanced or metastatic BTC. As a consequence,	

sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package leaflet has been updated accordingly. Version 7.1 of the RMP has also been submitted. ”	
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0121 Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst, “Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with stage IB (T2a ≥ 4 cm), II or IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete resection, based on study KEYNOTE-091; an ongoing Phase 3, randomized, triple-blinded, placebo-controlled, multicentre study of pembrolizumab versus placebo in patients with early-stage NSCLC after resection and completion of standard adjuvant therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are being updated and the Package Leaflet is updated in accordance. An updated RMP version 39.1 was also submitted.”	
Retsevmo - selpercatinib - EMEA/H/C/005375/II/0014/G Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst, “Extension of indication to include first-line treatment of advanced RET-mutant medullary thyroid cancer (MTC) in adults and adolescents 12 years and older based on interim results from study LIBRETTO-001 (LOXO-RET-17001) on the clinical safety and efficacy of selpercatinib in patients with RET-mutant MTC who are cabozantinib and vandetanib treatment-naïve (MTC:-Cab/-Van). LIBRETTO-001 is a global, multicohort, open-label, Phase 1/2 study in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection. The application also includes an updated Phase II Environmental Risk Assessment in order to reflect the patient population as per the approved indication.”	

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Trecondi - treosulfan - EMEA/H/C/004751/II/0014, Orphan

medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, "Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of study MC-FludT.16/NM; a randomised phase II interventional study aimed to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases. Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M, a Phase II trial to describe the safety and efficacy of Treosulfan based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.0 of the RMP has also been submitted."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

ADCETRIS - brentuximab vedotin - EMEA/H/C/002455/II/0102/G, Orphan

Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik

Edarbi - azilsartan medoxomil - EMEA/H/C/002293/II/0031

Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege

Ervebo - recombinant vesicular stomatitis

virus - Zaire ebolavirus vaccine (live) - EMEA/H/C/004554/II/0022/G
Merck Sharp & Dohme B.V., Rapporteur: Christophe Focke

Hepcludex - bulevirtide - EMEA/H/C/004854/II/0014/G, Orphan
Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson

LIVOGIVA - teriparatide - EMEA/H/C/005087/II/0010
Theramex Ireland Limited, Rapporteur: Daniela Philadelphy

Mosquirix - plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - EMEA/H/W/002300/II/0061/G
GlaxoSmithkline Biologicals SA, Rapporteur: Jan Mueller-Berghaus

Pemetrexed Accord - pemetrexed - EMEA/H/C/004072/II/0020
Accord Healthcare S.L.U., Generic, Generic of Alimta, Rapporteur: John Joseph Borg

Plegridy - peginterferon beta-1a - EMEA/H/C/002827/II/0067
Biogen Netherlands B.V., Rapporteur: Johann Lodewijk Hillege

Polivy - polatuzumab vedotin - EMEA/H/C/004870/II/0017/G, Orphan
Roche Registration GmbH, Rapporteur: Alexandre Moreau

Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0188
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Puregon - follitropin beta - EMEA/H/C/000086/II/0124
Organon N.V., Rapporteur: Peter Kiely

Pyramax - pyronaridine / artesunate - EMEA/H/W/002319/II/0031/G
Shin Poong Pharmaceutical Co., Ltd., Rapporteur: Jean-Michel Race

Simulect - basiliximab - EMEA/H/C/000207/II/0114/G
Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus

Spectrila - asparaginase -
EMEA/H/C/002661/II/0031
medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop

Stelara - ustekinumab -
EMEA/H/C/000958/II/0094/G
Janssen-Cilag International N.V., Rapporteur: Jayne Crowe

Trulicity - dulaglutide -
EMEA/H/C/002825/II/0064/G
Eli Lilly Nederland B.V., Rapporteur: Martina Weise

Vimizim - elosulfase alfa -
EMEA/H/C/002779/II/0037/G, Orphan
BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege

WS2258/G
Infanrix hexa-
EMEA/H/C/000296/WS2258/0315/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2264
Humalog-
EMEA/H/C/000088/WS2264/0194
Liprolog-
EMEA/H/C/000393/WS2264/0154
Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder

WS2275/G
GONAL-f-
EMEA/H/C/000071/WS2275/0156/G
Pergoveris-
EMEA/H/C/000714/WS2275/0078/G
Merck Europe B.V., Lead Rapporteur: Thalia Marie Estrup Blicher

WS2285/G
Humalog-
EMEA/H/C/000088/WS2285/0195/G
Liprolog-
EMEA/H/C/000393/WS2285/0155/G
Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Besremi - ropeginterferon alfa-2b -

EMEA/H/C/004128/II/0021
AOP Orphan Pharmaceuticals GmbH, Rapporteur: Janet Koenig, "Update of sections 4.8, 5.1 and 5.2 of the SmPC based on results from CONTINUATION-PV study. An open-label, multicentre, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first-line treatment (BAT) in patients with polycythaemia vera who previously participated in the PROUDPV study. The Package Leaflet is updated accordingly."

Bydureon - exenatide - EMEA/H/C/002020/II/0074
AstraZeneca AB, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add cholelithiasis and cholecystitis to the list of adverse drug reactions (ADRs) with frequency (unknown) based on the cumulative review of pre-clinical and clinical study data, post-marketing data, medical/scientific literature and signal searches in internal and external databases on 'Gallbladder-related disorders' and exenatide.
The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC."

BYETTA - exenatide - EMEA/H/C/000698/II/0078
AstraZeneca AB, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add cholelithiasis and cholecystitis to the list of adverse drug reactions (ADRs) with frequency (unknown) based on the cumulative review of pre-clinical and clinical study data, post-marketing data, medical/scientific literature and signal searches in internal and external databases on 'Gallbladder-related disorders' and exenatide.
The Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Evrenzo - roxadustat - EMEA/H/C/004871/II/0002
Astellas Pharma Europe B.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add dermatitis exfoliative generalised (DEG) to the list of adverse drug reactions (ADRs) with frequency

unknow based on post-marketing data and literature. In addition, the MAH took the opportunity to amend the Annex IIB in order to reflect the fact that restricted prescription applies. Furthermore, the MAH took the opportunity to implement editorial changes to the SmPC."

Eylea - aflibercept - EMEA/H/C/002392/II/0080

Bayer AG, Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 5.1 of the SmPC in order to allow the individualisation of the treatment posology for intravitreal aflibercept in diabetic macular oedema (DME) indication based on a propensity-score-matching (PSM) analyses on patient-level-data comparison of the two pivotal studies in DME (VIVID & VISTA) versus the independently conducted Protocol T study as well as supporting data from a systematic literature review and confirmatory data from the recently completed VIOLET Phase 3b study. The Package Leaflet is updated accordingly."

Fexinidazole Winthrop - fexinidazole - EMEA/H/W/002320/II/0010

sanofi-aventis groupe, Rapporteur: Fátima Ventura, "Update of section 4.4 of the SmPC in order to add a new warning on severe irreversible hepatotoxicity in patients with Cockayne syndrome based on case reports and literature reviews; the Package Leaflet is updated accordingly."

Imbruvica - ibrutinib - EMEA/H/C/003791/II/0074

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of section 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the information related to Paediatrics following assessment done in procedure P46/035, based on results from the paediatric study LYM3003 "A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Paediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma".
The Package Leaflet is updated accordingly."

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0047/G

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "Submission of the final reports from the non-clinical studies TV-TEC-207316, TV-TEC-207437, TOX15155, TV-TEC-215524 and TOX15252, listed as category 3 in the RMP. These are non-clinical studies conducted to further characterise the potential mechanisms underlying the important identified risks of thrombosis with thrombocytopenia syndrome (TTS) and thrombocytopenia, including immune thrombocytopenia (ITP)."	
Onpattro - patisiran - EMEA/H/C/004699/II/0025, Orphan Alnylam Netherlands B.V., Rapporteur: Kristina Dunder, "Update of sections 4.2 and 5.1 of the SmPC based on interim results from study ALN-TTR02-006 listed as a category 3 study in the RMP; this is a multicentre, open-label, extension study to evaluate the long-term safety and efficacy of patisiran in patients with familial amyloidotic polyneuropathy who have completed a prior clinical study with patisiran. In addition, the MAH took the opportunity to update section 3 of the SmPC ."	
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0009 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.3 and 4.5 of the SmPC in order to remove piroxicam as a contraindicated medicinal product based on scientific literature. The package leaflet is updated accordingly."	
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0010/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC to add hypersensitivity to the list of adverse drug reactions with frequency common, based on a cumulative search of the MAH safety database; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to	

add drug-drug interaction information with dabigatran (P-gp substrate) based on the clinical study results from study C4671012, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of dabigatran; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to update the drug-drug interaction information of midazolam based on the clinical study results from study C4671013, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of midazolam. The MAH is taking the opportunity to include editorial updates in sections 4.3 and 6.1 of the SmPC.”	
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0012/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Submission of the whole body autoradiographic study report in rats with PF-07321332 (alone) in order to fulfil LEG/002 and the final study report for the pre- and postnatal development (21GR149) in order to fulfil LEG/004; this is an oral (gavage) study of the effects of PF-07321332 on pre- and post-natal development, including maternal function in rats.”	
Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0112 Zr Pharma& GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, “Update of section 4.8 of the SmPC in order to include information on post-treatment recovery in growth based on final results from study YV25718 listed as a category 3 study in the RMP; this is a Phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO0258310) compared to untreated control in children with HBeAg-Positive Chronic Hepatitis B in the immune active phase. The RMP version 9.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the Package Leaflet.”	

Rybelsus - semaglutide - EMEA/H/C/004953/II/0025

Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add 'Hypersensitivity' to the list of adverse drug reactions (ADRs) with frequency uncommon; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0009

Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik, "Update of sections 5.3 and 6.6 of the SmPC based on final results from MVT-601-9030_Relugolix_ZEOGRT_Study (Rec); this is a fish, full life cycle test performed in the context of the Environmental Risk Assessment of relugolix.
The Package Leaflet is updated accordingly."

Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0054

GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, "Update of section 4.5 of the SmPC based on final results from study ZOSTER-059; this is a Phase IIIB, open label, randomised, controlled study to evaluate the immunogenicity, safety and reactogenicity of Shingrix when co-administered with Prevenar 13 in adults ≥ 50 years of age.
In addition, the MAH took the opportunity to update section 4.5 of the SmPC to update the existing statement to specify the incidence percentages of fever and shivering upon co-administration of Shingrix with PPV23 based on study ZOSTER-035."

SonoVue - sulphur hexafluoride - EMEA/H/C/000303/II/0049

Bracco International B.V., Rapporteur: Alexandre Moreau, "Update of sections 4.1, 4.4 and 5.1 of the SmPC based on final results from study BR1-145 listed as a PAES in the Annex II; this is an observational, retrospective, multicentre, comparative study conducted in patients below 18 years of age who had undergone a VUS exam with intravesically administered SonoVue/Lumason or a VCUG

exam as part of their standard of care for evaluation of known or suspected VUR."

TAGRISSO - osimertinib - EMEA/H/C/004124/II/0047

AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.2 of the SmPC based on final results from studies ODIN-BM and ODIN-HV; these are two phase I clinical pharmacology studies conducted in EGFRm+ NSCLC patients (ODIN-BM) and healthy volunteers (ODIN-HV) to determine osimertinib blood-brain barrier (BBB) penetration and brain distribution in patients with brain metastases and healthy volunteers with an intact BBB, respectively."

TECFIDERA - dimethyl fumarate - EMEA/H/C/002601/II/0078

Biogen Netherlands B.V., Rapporteur: Martina Weise, "Submission of the final report from study 109MS408; upon request by the PRAC as per final PSUR assessment report of procedure EMEA/H/C/PSUSA/00010143/20213. This is a Multicentre, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing Remitting Multiple Sclerosis in the Real-World Setting (PROTEC)."

Trecondi - treosulfan - EMEA/H/C/004751/II/0016, Orphan

medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study MC-FludT.14/L Trial II; a phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.
The Package Leaflet is updated accordingly."

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0074

AstraZeneca AB, Rapporteur: Sol Ruiz, "Type II C.I.11.b, To update Annex IIE to remove the

specific obligation relating to provision of process validation data for the active substance and finished product (SO1) which has been fulfilled, and to change the date of the specific obligation relating to the provision of additional information on stability of the active substance and finished product (and review the finished product specifications following further manufacturing experience) from June 2022 to January 2023 (SO2)."

Veklury - remdesivir - EMEA/H/C/005622/II/0037/G

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Grouped variations to update sections 4.5, 5.2 and 6.6 of the SmPC to update prescribing information related to interactions with other medicinal products, effect of intrinsic factors and COVID-19 disease on the pharmacokinetics (PK) of Veklury and its metabolites in the adult population. Data from the Phase 1 drug-drug interaction (DDI) study GS US 540 9013, adult COVID-19 participant PK data collected across two Phase 3 studies (GS-US-540-9012 and CO-US-540-5844), and an exposure-safety analysis are included in addition to nonclinical in vitro drug metabolism studies to complete the metabolism profiling. This variation is submitted to cover Recommendations 9, 11, 12 and 13 listed at the time of the conditional marketing authorization (EMEA/H/C/005622/0000) for Veklury. Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce some linguistic amendments."

B.6.10. CHMP-PRAC assessed procedures

HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0078

Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety data in paediatric population based on final results from study 161504 – Post-Authorisation Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Paediatric Subjects With Primary Immunodeficiency Diseases, listed as a category 3 study in the RMP. This is a paediatric

interventional Phase 4 study performed to acquire additional data on safety, tolerability and immunogenicity of HyQvia in paediatric (age two to <18 years) patients with Primary Immunodeficiency Diseases (PIDD).
In addition, the MAH is taking this opportunity to update Annex II-D of the PI following procedure EMEA/H/C/002491/II/0070/G.
The RMP version 13.1 has also been submitted."

Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0064

Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark, "Submission of the final report from study BO28407 (KAITLIN): A randomized, multicentre, open-label, Phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer listed as a category 3 study in the RMP.
The RMP version 15.0 has also been submitted."

Ontozry - cenobamate - EMEA/H/C/005377/II/0009

Angelini S.p.A., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 5.3 of the SmPC in order to update information on toxicity to reproduction and development based on final results from nonclinical study "Effects of Cenobamate (YKP3089) on Embryo-Fetal Development in Rats after Twice Daily Oral Administration".
The RMP version 3.0 has also been submitted."

Spikevax - elasomeran - EMEA/H/C/005791/II/0062

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Submission of an updated RMP version 4.0 in order to remove 'anaphylaxis' as an important identified risk; to remove 'interaction with other vaccines' as a safety concern in study mRNA-1273-P904 following the outcome of the EMEA/H/C/005791/MEA/004.4 procedure; to implement the WHO-approved INN 'elasomeran'; to update the study milestones for the mRNA-1273-P301, mRNA1273-P203,

mRNA-1273-P201, mRNA-1273-P901, mRNA-1273-P903 and mRNA-1273-P910 studies and to add study mRNA-1273-P911 to the RMP. The Annex II of the Product Information is updated accordingly."	
Trecondi - treosulfan - EMEA/H/C/004751/II/0012, Orphan medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with regards to CYP3A4, CYP2C19 and P-gp including physiologically based pharmacokinetic (PBPK) modelling. Version 1.0 of the RMP has also been submitted."	
Trecondi - treosulfan - EMEA/H/C/004751/II/0013, Orphan medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, "Update of section 5.3 of the SmPC in order to update the description of non-clinical information regarding musculoskeletal and connective tissue disorders in form of lympho-histiocytic infiltration in the skeletal muscles and renal and urinary disorders which show up as haematuria. These new determinations are based on results from study LPT 37259. A revised RMP version 1.0 was also submitted."	
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0075 AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 5.1 of the SmPC in order to include updated efficacy information based on the 6 months follow-up analysis from study D8110C00001 listed as a specific obligation in the Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicentre study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria. The RMP version 5.1 has also been submitted. The MAH removed the important identified risk of anaphylaxis from the list of safety concerns, updated the routine and additional pharmacovigilance activities section and took the opportunity to implement other	

administrative updates."

WS2274
Relvar Ellipta-
EMEA/H/C/002673/WS2274/0054
Revinty Ellipta-
EMEA/H/C/002745/WS2274/0052
GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Maria del Pilar Rayon, "Submission of the final report from study HZA114971 listed as a category 3 study in the RMP. This is a multicentre randomised, double-blind, placebo-controlled, parallel-group study to evaluate the effects of a one-year regimen of orally inhaled fluticasone furoate 50 mcg once daily on growth velocity in prepubertal, paediatric subjects with asthma. The RMP version 11.1 has also been submitted."

B.6.11. PRAC assessed procedures

PRAC Led
Brintellix - vortioxetine -
EMEA/H/C/002717/II/0037
H. Lundbeck A/S, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from study PASS 16034N listed as a category 3 study in the RMP. This is a non-interventional post-authorisation safety study (PASS) of vortioxetine in Europe - An analysis of European automated healthcare databases. The RMP version 4.0 has also been submitted."

PRAC Led
Duavive - estrogens conjugated / bazedoxifene -
EMEA/H/C/002314/II/0032
Pfizer Europe MA EEIG, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of an updated RMP version 3.2 in order to reflect the updated study milestones and completion of the post-authorisation safety study of CE/BZA in the United States (US PASS, Study B2311060) previously assessed as part of II/0030 (MEA002.15), as well as to update the post-marketing data with the data lock point of 31 October 2021."

PRAC Led

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0048/G

Janssen-Cilag International N.V., PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final reports from four exploratory studies conducted to further characterise the potential mechanisms underlying the important identified risk of thrombosis with thrombocytopenia syndrome (TTS). These studies evaluated the levels of anti-PF4 antibodies using clinical samples, both from Ad26.COV2.S and other non-COVID-19 Ad26-based vaccine clinical studies. Interim results from an additional exploratory study are provided and the submission milestone for the final results has been updated. The RMP version 4.1 has been submitted and updated in line with this procedure and the ongoing procedure EMEA/H/C/005737/II/0047/G. In addition, the MAH removed the important identified risk of anaphylaxis from the list of safety concerns (PSUSA/00010916/202108), updated the routine pharmacovigilance activities section and took the opportunity to implement other administrative updates in the RMP in alignment with procedure EMEA/H/C/005737/II/033. "

PRAC Led

WS2261

Lyrica-EMEA/H/C/000546/WS2261/0118

Pregabalin Pfizer-EMEA/H/C/003880/WS2261/0047

Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To update SmPC sections 4.4 and 4.8 with a warning regarding severe cutaneous adverse reactions (SJS and TEN); the PL was updated accordingly."

PRAC Led

WS2268

Dovato-EMEA/H/C/004909/WS2268/0031

Juluca-EMEA/H/C/004427/WS2268/0044

Tivicay-EMEA/H/C/002753/WS2268/0079

Triumeq-EMEA/H/C/002754/WS2268/0104

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Martin

Huber, PRAC-CHMP liaison: Martina Weise, "To update section 4.8 of the SmPC and section 4 of the PL to include the ADR "weight increased" with a frequency "common".
In addition, the marketing authorisation holder has taken the opportunity to implement a minor editorial change in the German SmPC for Juluca."

B.6.12. CHMP-CAT assessed procedures

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0055, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0056, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, "Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy and safety information in paediatric population based on study CCTL019C2202, a phase II, single arm, multicentre open label trial to determine the safety and efficacy of tisagenlecleucel in paediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA).
The Package Leaflet is updated accordingly."

WS2269
Tecartus- EMEA/H/C/005102/WS2269/0022
Yescarta- EMEA/H/C/004480/WS2269/0051
Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

B.6.13. CHMP-PRAC-CAT assessed procedures

Tecartus - brexucabtagene autoleucel - EMEA/H/C/005102/II/0019, Orphan, ATMP
Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.8 and 5.1 of the

SmPC in order to update the safety and efficacy information based on 24-month follow-up data from all treated patients in cohort 1 of the pivotal clinical study, KTE-C19-102 (ZUMA-2); a Phase 2, multicentre, open-label study evaluating the safety and efficacy of KTE-X19 in subjects with relapsed or refractory (r/r) mantle cell lymphoma (MCL). This submission is in fulfilment of the specific obligation (SOB 004) to confirm the long-term efficacy and safety of Tecartus in adult patients with relapsed/refractory (r/r) MCL. In addition, the MAH has taken the opportunity to make minor editorial changes in the SmPC. The RMP version 2.1 has also been submitted."	

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2219/G **Fluenz Tetra-** **EMEA/H/C/002617/WS2219/0116/G** **Pandemic influenza vaccine H5N1** **AstraZeneca-** **EMEA/H/C/003963/WS2219/0050/G** AstraZeneca AB, Lead Rapporteur: Christophe Focke	
WS2251/G **Eucreas-** **EMEA/H/C/000807/WS2251/0097/G** **Icandra-** **EMEA/H/C/001050/WS2251/0101/G** **Zomarist-** **EMEA/H/C/001049/WS2251/0099/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder	
WS2260 **Stayveer-** **EMEA/H/C/002644/WS2260/0036** **Tracleer-** **EMEA/H/C/000401/WS2260/0101** Janssen-Cilag International N.V., Lead Rapporteur: Alexandre Moreau	
WS2262 **Hexacima-** **EMEA/H/C/002702/WS2262/0130** **Hexyon-**	

EMEA/H/C/002796/WS2262/0134
Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus

WS2272/G
Hexacima-
EMEA/H/C/002702/WS2272/0131/G
Hexyon-
EMEA/H/C/002796/WS2272/0135/G
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

WS2278/G
Copalia-
EMEA/H/C/000774/WS2278/0125/G
Copalia HCT-
EMEA/H/C/001159/WS2278/0100/G
Dafiro-
EMEA/H/C/000776/WS2278/0129/G
Dafiro HCT-
EMEA/H/C/001160/WS2278/0102/G
Exforge-
EMEA/H/C/000716/WS2278/0124/G
Exforge HCT-
EMEA/H/C/001068/WS2278/0099/G
Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher

WS2279/G
Ebymect-
EMEA/H/C/004162/WS2279/0057/G
Xigduo-
EMEA/H/C/002672/WS2279/0067/G
AstraZeneca AB, Lead Rapporteur: Kristina Dunder

WS2287/G
Filgrastim Hexal-
EMEA/H/C/000918/WS2287/0064/G
Zarzio-
EMEA/H/C/000917/WS2287/0065/G
Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillege

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time-Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 16-19 May 2022 CHMP plenary:

G.2.2. List of procedures starting in May 2022 for June 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address